

Brigard & Castro

Abogados

Apartado 3692

Cra. 7 16-56
Bogotá - Colombia S.A.

Tel. Conm. 3802200
Tel./Fax: (57.1) 2827976
(57.1) 3802700

E-Mail: bricas@brigardycastro.com.co

AS: 83.664

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
Radicación : 00091771 00000002 Folios: 43
Fecha (999): 2001-05-11 17:49:16
Tramite : 002 PATENTES D 1 REGISTRO/ 444 REPUESTA
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

Señores

**SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES**

E. S. D.

REF: Expediente No. 00 091.771 - Solicitud de Patente
a favor de UCB, S.A.

Titulada: UN DERIVADO DE PIRROLIDINACETAMIDA SOLO O EN
COMBINACIÓN PARA EL TRATAMIENTO DE TRASTORNOS DEL
SISTEMA NERVIOSO CENTRAL (CNS)

RAMIRO CASTRO DUQUE, vecino de Bogotá, portador de la tarjeta profesional No. 1003, obrando como apoderado de la sociedad UCB, S.A., según lo acredita el documento de poder presentado en esa División, para dar cumplimiento al requerimiento notificado por fijación en lista de fecha 15 de Marzo de 2001, y de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la Comunidad Andina, me permito informar, y anexar al presente escrito los siguientes documentos:

1. Documento de cesión de derechos sobre la invención conferido por el solicitante, debidamente legalizado y autenticado ante Cónsul Colombiano, y autenticado ante el Ministerio de Relaciones Exteriores junto con su correspondiente traducción al castellano, debidamente avalada por el Ministerio de Relaciones Exteriores.
2. La dirección del solicitante es: allée de la Recherche 60, 1070 Bruselas, BÉLGICA
3. Extracto para publicación y Tarjeta de archivo temático.
4. Copias certificadas por la Oficina Europea de Patentes de las dos primeras solicitudes presentadas para la misma invención, de las cuales REIVINDICAMOS PRIORIDAD, junto con sus correspondientes traducciones del inglés al castellano.

Brigard & Castro
Abogados

73
A
Apartado 3892

Cra. 7 16-56
Bogotá - Colombia S.A.

Tel. Conn. 3802200
Tel./Fax: (57.1) 2827976
(57.1) 3802700

E.Mail:bricas@brigardycastro.com.co

Del señor Jefe atentamente,



RAMIRO CASTRO DUQUE

C.C. No. 170.322 de Bogotá

Código 340

Cra 7a. No. 16-56 Piso 9

Santafé de Bogotá, Mayo 10, 2001

CPB/hsr

Folios 74 correspondiente a torjeta y
75 correspondiente a extracto de
publicación

74 83664 26
/6



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99124269.4

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

**DEN HAAG, DEN
THE HAGUE, 03/11/00
LA HAYE, LE**



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

75

~~27~~
~~27~~

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.: 99124269.4
Demande n°:

Anmeldetag:
Date of filing: 01/12/99
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
UCB, S.A.
1070 Bruxelles
BELGIUM

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Use of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide for treatment of bipolar and pain disorders

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
A61K31/40

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

Titre original: voir page 1 de la description

USE OF (S)-(-)- α -ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE FOR THE PREPARATION
OF A DRUG


The present invention relates to the use of (S)-(-)- α -ethyl-2-oxo-1-
5 pyrrolidineacetamide for the preparation of drugs for the curative and/or prophylactic
treatment of bipolar disorders, migraine, chronic or neuropathic pain.

The use of levorotatory (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide, also known as
levetiracetam [International Nonproprietary Name] as a protective agent for the treatment
and prevention of hypoxic and ischaemic type aggressions of the central nervous system
10 is described in the Applicant's European patent EP-A-0162 036. That compound can also
be employed in the treatment of epilepsy, a therapeutic indication for which it has been
demonstrated that its dextrorotatory enantiomer, (R)-(+)- α -ethyl-2-oxo-1-pyrrolidine-
acetamide, is completely devoid of activity (A. J. GOWER *et al.*, Eur. J. Pharmacol., 222,
(1992), 193-203). That compound has also been described in European patent EP-A-
15 0 645 139, also in the Applicant's name, for the treatment of anxiety.

EP-A-162 036 cited above also describes methods for preparing (S)-(-)- α -ethyl-2-
oxo-1-pyrrolidine-acetamide which require the synthesis of a starting reactant obtained
by resolution of the corresponding racemate. British patent GB-A-2 225 322, also in the
Applicant's name, describes a method for preparing that compound which offers the
20 advantage of using a natural amino acid which already has the desired stereochemical
configuration as the starting material, thus dispensing with any laborious separation of
the enantiomers.

In continuing its research on that compound, the Applicant has now discovered
that (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide possesses therapeutic properties which
25 render it particularly useful in the treatment and prophylaxis of bipolar disorders, mania,
migraine, chronic or neuropathic pain. Further, these activities were not observed for the
dextrorotatory enantiomer, (R)-(+)- α -ethyl-2-oxo-1-pyrrolidineacetamide.

The present invention thus concerns the use of (S)-(-)- α -ethyl-2-oxo-1-
pyrrolidineacetamide with formula:



for the preparation of drugs for the treatment or prophylaxis of bipolar disorders, mania, migraine, chronic or neuropathic pain.

The present invention also concerns a method for treating migraine, bipolar disorders, chronic or neuropathic pain, comprising administering a therapeutic dose of
5 (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide to a patient.

The term "treatment" as used by the Applicant means curative treatment and prophylactic treatment.

By "curative" we mean the efficaciousness of Levetiracetam in treating the current episode (e.g., like a manic phase or a depressive phase in bipolar).

10 By "prophylactic" or "maintenance" we mean the prevention of the recurrence of manic/depressive, migraine, chronic or neuropathic pain episodes.

In a first aspect, the invention concerns the use of (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or prophylactic treatment of migraine disorder.

15 The term "migraine" as used by the Applicant means a disorder characterized by recurrent attacks of headache that vary widely in intensity, frequency, and duration. The attacks are commonly unilateral and are usually associated with anorexia, nausea, vomiting, phonophobia, and/or photophobia. In some cases they are preceded by, or associated with, neurologic and mood disturbances. Migraine headache may last from 4
20 hours to about 72 hours. The International Headache Society (IHS, 1988) classifies migraine with aura (classical migraine) and migraine without aura (common migraine) as the major types of migraine. Migraine with aura consists of a headache phase preceded by characteristic visual, sensory, speech, or motor symptoms. In the absence of such symptoms, the headache is called migraine without aura.

25 One-year prevalence figures are primarily dependent on age and sex (Ferrari MD. "Migraine" The Lancet (1998); 351: 1043-1051 - Sheffield RE. "Migraine prevalence: a literature review" Headache (1998); 38: 595-601).

Ten percent of the general population (6% of males and 15% of females) are active migrainers. Prevalence peaks around 35 to 50 years of age in women and 25 to 35
30 years of age in men. Within the 10 to 19 years age group, there is a sharp increase in prevalence with age, with a peak around 14-15 years. Before puberty there is an equal prevalence between males and females. Among adults, the ratio of women to men is approximately 2.5 : 1. One-year prevalence rates for migraine without aura are 1.5 to 7 times higher than migraine with aura.

35 Migraine treatments can be divided into four types: general measures, abortive therapy, pain relief measures, and prophylactic treatment (Silberstein SD. "Preventive treatment of migraine: an overview" Cephalalgia (1997); vol. 17 p 67-72 - Diamond S,

Diamond ML. *"Contemporary diagnosis and management of headache and migraine"* (1998); First Edition. Handbooks in Health Care Co., Newtown, Pennsylvania, USA.

Diener HC, Kaube H, Limmroth V. *"A practical guide to the management and prevention of migraine"* Drugs (1998); vol. 56 (5): p 811-824).

5 General measures may be a regular sleep schedule, regular meal schedule, dietary measures, etc. There are a variety of agents that may be used as abortive treatments, ranging from the simple analgesics such as acetyl salicylic acid, non-steroidal anti-inflammatory drugs (NSAIDs), ergot compounds, antiemetics, to the most recently developed serotonin (5-HT) agonists (triptan compounds).

10 Pain relief measures may include NSAIDs, narcotic analgesics, or rescue therapy. As for acute treatments there is a variety of medications that are used in the prophylaxis of migraine. Prophylactic treatment is usually given daily for months or years. It should be considered for patients who have two or more migraine attacks per month. Beta-adrenoceptor blockers - primarily propranolol- have been recognized for
15 their efficacy in migraine prevention. Equally efficacious is the antiepileptic drug divalproex sodium. Other compounds are tricyclic antidepressants (amitriptyline), calcium channel blockers (nifedipine, flunarizine, verapamil), NSAIDs (ketoprofen, naproxen), riboflavin (vitamin B2), and 5-HT antagonists.

20 Traditional theories of migraine pathogenesis are the vasogenic theory and the neurogenic theory. Neither of these theories completely explains all of the clinical phenomena observed during a migraine attack.

25 Current views on migraine pathophysiology take into account both neurological and vascular events in the initiation of an attack. Endogenous neurophysiologic events activate trigeminovascular fibers in the brainstem, with subsequent perivascular release
30 of powerful vasoactive neuropeptides. In animal experiments these neuropeptides promote a neurogenic inflammation response, consisting of vasodilatation and dural plasma extravasation. Cortical spreading depression (CSD) has been described as slowly spreading waves of inhibition of cortical neurons that is associated with the clinical symptoms of aura. Experimental CSD can activate the trigemino-vascular system
35 in the brainstem, providing a possible link between aura and headache mechanisms.

 There is some evidence that 5-HT acts as a neurotransmitter and humoral mediator in the neural and vascular components of the migraine headache.

 Migraine patients have a systemic disturbance of the 5-HT metabolism.

 It is theorized that persons prone to migraine have a reduced threshold for
35 neuronal excitability, possibly due to diminished activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). GABA normally reduces the cellular

effects of the neurotransmitter serotonin (5-HT) and glutamate, both of which appear to be involved in migraine attacks.

Divalproex sodium is a stable co-ordination compound comprising sodium valproate and valproic acid in a 1:1 molar relationship. Disordered GABA metabolism has been reported in migraine patients and changes in cerebrospinal GABA levels were found during migraine episodes. Divalproex is thought to elevate brain levels of gamma-aminobutyric acid (GABA) by decreasing its degradation. The increased activity of GABAergic systems may influence the migraine generation directly or indirectly through a number of mechanisms. Potential indirect mechanisms include decreasing the firing rate of the serotonergic neurons in the dorsal raphe nucleus.

Valproate has been reported to raise endogenous brain levels of enkephalin, which plays a determinant role in analgesia.

It has been postulated that valproate decreases levels of excitatory amino acids in the brain, interfering with CSD (Mathew NT and col., "Migraine prophylaxis with divalproex" Arch. Neurol. (1995); vol.52: p 281-286 - Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. "The concept of migraine as a state of central neuronal hyperexcitability" Neurol. Clin. (1990); vol.8: p 817-828).

The most common side effects reported with divalproex are nausea, vomiting, indigestion, asthenia, somnolence, dizziness, tremor, weight gain, and alopecia. Because most side effects are dose related, patient and physician should aim for the lowest possible therapeutic dose.

Valproate has a known risk of hepatic failure, particularly in young children. Liver function tests need to be performed at regular intervals. Valproate has been reported to produce teratogenic effects such as neural tube defects. The latter demand that the benefits of its use be weighed against the risks of its use in women of childbearing potential, particularly in treatment conditions such as for migraine prophylaxis.

There is a genuine need to develop other alternatives and to provide a compound with a therapeutic margin that is more appropriate to the treatment of this pathology.

Clinical trials carried out by the applicant have surprisingly demonstrated that (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide (levetiracetam) is particularly suitable for the treatment of migraine directly or prophylactically.

These results are particularly unexpected due to the fact that levetiracetam is devoid of direct effects on the GABA system (H. Klitgaard and col., "Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy" European Journal of Pharmacology (1998); vol. 353, p. 191-206). Potentiation of GABAergic inhibition has been proposed but extensive in vitro experiments have not revealed any significant

displacement of ligands specific for 55 different binding sites including different receptor systems, reuptake sites, second messenger systems and channel proteins (M. Noyer and col. *"The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes"* European Journal of Pharmacology (1995), vol. 286, p 137-146). Furthermore, levetiracetam did not modulate chloride fluxes induced by muscimol (unpublished data). Finally, a lack of effect on GABA levels and the enzymatic activities of GABA transaminase and glutamic decarboxylase was reported from a neurochemical study on mouse brain (G. J. Sills and col. *"Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain"*, European Journal of Pharmacology; (1997) vol. 325 p 35-40).

Valproate is moreover the only antiepileptic drug that has been approved for its efficacy in the prophylactic treatment of migraine headache, thus, it was unexpected for the applicant to discovered that (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide (levetiracetam) is also particularly suitable for the treatment and/or prophylactic treatment of migraine.

In a further aspect, the invention concerns the use of (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or prophylactic treatment of bipolar disorders.

The term "bipolar disorders" as used by the Applicant is defined below.

Bipolar disorders are classified as Mood Disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TM), American Psychiatry Association, Washington, DC, 1994). Bipolar disorders are generally characterized by spontaneously triggered repeated (i.e. at least two) episodes in which the patient's hyperexcitability, activity and mood are significantly disturbed, this disturbance consisting on some occasions of an elevation of mood and increased energy and activity (mania or hypomania), and in other occasions a lowering of mood and decreased energy and activity (depression).

Bipolar disorders are separated into four main categories in the DSM-IV (bipolar I disorder, bipolar II disorder, cyclothymia, and bipolar disorders not otherwise specified).

The essential feature of bipolar I disorder is a clinical course that is characterized by one or more manic episodes alternated with one or more major depressive episodes.

The essential feature of bipolar II disorders is a clinical course that is characterized by one or more major depressive episodes accompanied by at least one hypomanic episode. No full manic or mixed episodes are present.

Cyclothymia is characterized by numerous periods of hypomanic symptoms that do not meet criteria for a manic episode and periods of depressive symptoms that do not meet symptom or duration criteria for a major depressive episode.

Bipolar disorders not otherwise specified may be made in addition to the diagnosis of schizophrenia, delusional disorders, or psychotic disorder not otherwise specified. If there is a very rapid alternation (over days) between manic symptoms and depressive symptoms (e.g., several days of purely manic symptoms followed by several days of purely depressive symptoms) that do not meet minimal duration criteria for a manic episode or major depressive episode, the diagnosis is bipolar disorders not otherwise specified.

By manic episode, the applicant means a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood with signs of pressured speech and psychomotor agitation.

By hypomania, the applicant means a less extreme manic episode, with lower grade of severity.

By major depressive episode, the applicant means a period of at least 2 weeks during which there is either depressed mood or the loss of interest or pleasure in nearly all activities with signs of impaired concentration and psychomotor retardation.

By mixed episode, the applicant means a period of time (lasting at least 1 week) in which the criteria are met both for a manic episode and for a major depressive episode nearly every day.

For a number of decades, the treatment of mania and manic recurrences in bipolar disorders has essentially been based on the use of lithium salts (Li^+). In recent years, the incomplete protection and tolerance furnished by long-term use of Li^+ for bipolar disorders has led to alternative treatments being considered. Clinical studies indicate that during the acute phase of bipolar disorder, up to 40% of patients do not satisfactorily respond to lithium treatment (Gustavo A. et al., *Anticonvulsants for treatment of manic depression*; Current Drug Therapy, vol. 56, N°8, 1989).

A number of safety problems linked to long-term use of lithium have been observed. Thus chronic interstitial nephropathy, polyuria, diabetes insipidus or nephrogenic diabetes insipidus occur in 25% of subjects treated over a period of more than two years. Further, normal use of lithium frequently induces dysarthria, trembling, ataxia, hypothyroidism (30% of subjects in the first two years) and impotence.

One of the most common alternative treatments is the use of an anticonvulsant, valproic acid (or its sodium salt), which has been shown to have an antimanic activity and is also capable of having a mood stabilizing activity. However, the results obtained are not yet satisfactory, and moreover valproic acid readily induces a variety of side effects. The usual side effects of valproic acid relate to the gastro-intestinal tract, such as nausea, vomiting, anorexia and diarrhea, as described in the preceding paragraph.

79

Pharmacological tests carried out by the Applicant have demonstrated that in therapeutically active doses, valproic acid would induce significant hyperactivity when given to a healthy control rodent. The prophylactic use of valproate could therefore induce an effect contrary to the desired effect and/or produce a slight hyperactivity after each administration of a tablet. Similarly, during active treatment, valproate is capable of maintaining a hyperactive effect although the manic phase has passed. Finally, this study has demonstrated the difficulty of adapting the useful dose of lithium or valproic acid to the subject. Thus for these two compounds, a slight overdose tends to reduce rodent activity to below the level of the controls.

There is a genuine need to develop other alternatives to lithium or to valproic acid to avoid their numerous side effects and to provide a compound with a therapeutic margin, which is more appropriate to the treatment of this pathology.

On continuing its research in this field, the Applicant has surprisingly discovered that (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide (levetiracetam), in addition to its antimanic activity, only induces a very slight hyperactivity in control rats with no sign of mania. Levetiracetam would thus be particularly suitable for the treatment of mania directly or prophylactically.

A further unexpected advantage of levetiracetam is the provision of normalization to the level of the activity of the control, while valproate or lithium tend to go beyond this.

Thus in the case of valproate and lithium, too high a dose of these compounds could result in underactivity with respect to the normal state of the patient, which should be avoided.

Levetiracetam thus has a certain advantage, as it enables the practitioner to adapt the doses to the patient more easily, without risking inducing side effects of hypoactivity due to overdosing.

Similarly, the consequences of abusive intake of tablets by the patient would be minimized.

Finally, in the therapeutic doses used, levetiracetam also has the advantage of being far removed from doses at which it is capable of inducing side effects while compounds such as valproic acid or carbamazepine have a much reduced margin of safety (A. J. Gower et al., Eur. J. Pharmacol., 22, p 193-203 (1992) – W. Löscher and D. Hönack, Eur. J. Pharmacol., 232, p 147-158 (1993) – H. Klitgaard, A. Matagne, J. Gobert, E. Wülfert, Eur. J. Pharmacol., 353, p 191-206 (1998)).

This unforeseeable range of properties means that the use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide is of particular interest for the manufacture of a medicament for

treatment and/or prophylactic treatment of bipolar disorders. This compound has a safety margin in use which has never been achieved for this therapeutic category.

In a further aspect, the invention concerns the use of (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or
5 prophylactic treatment of chronic and/or neuropathic pain disorders.

The term "chronic pain" as used by the Applicant is gradually being recognised as a disease process distinct from acute pain. Conventionally defined as pain that persists beyond the normal time of healing, pain can also be considered chronic at the point when the individual realises that the pain is going to be a persistent part of their
10 lives for the foreseeable future. It is likely that a majority of chronic pain syndromes involves a neuropathic component, which is usually harder to treat than acute somatic pain.

The best examples of predominantly neuropathic pain syndromes are diabetic peripheral neuropathy and post herpetic neuralgia. A primarily somatic chronic pain
15 syndrome is exemplified by patients with rheumatoid arthritis or other rheumatologic diseases. On the other hand, the most common chronic pain syndrome involving back injury related pain often involves multiple organ systems. The other major cause of chronic pain is cancer, which is known for its ability to cross tissue boundaries and damage or compress a variety of organ systems. Therefore, most back injury and cancer
20 patients have pain related to both somatic and neuropathic mechanisms (H. C. Hansen, MD "Treatment of chronic Pain With Antiepileptic Drugs: A New Era" South Medical Journal- Southern Medical Association (1999) 92(7) p 642-649).

The term "neuropathic pain" as used by the Applicant, is a pain initiated by a pathological change in a nerve which signals the presence of a noxious stimulus when no
25 such recognisable stimulus exists, giving rise to a false sensation of pain. In other words, it appears that the pain system has been turned on and cannot turn itself off.

It may be related to peripheral or central (spinal or brain) nerve lesions or dysfunction in the nervous system. Neuropathic pain can manifest as a result of conditions such as, nerve injury (e.g. surgery, accident, amputation), trauma affecting
30 the limb (with or without obvious nerve lesions), diseases affecting the nervous system, infarct related to the nervous system, abnormal nerve function, spinal and radicular pain disorders.

By nerve injury, the applicant means conditions such as, phantom pain (pain referred to the amputated limb), stump pain (pain at the amputation site), phantom limb
35 (non-painful sensations referred to the amputated limb), post-operative pain, thalamic pain syndrome (central post-stroke pain). By trauma affecting the limb, the applicant means conditions such as, reflex symptomatic dystrophy, Causalgia. By diseases

affecting the nervous system, the applicant means conditions such as, diabetic neuropathy and other neuropathies, trigeminal neuralgia (TN), postherpetic neuralgia (PHN), multiple sclerosis, AIDS-related neuropathy, Cancer-related neuropathy (neuropathy secondary to chemotherapy) (S. Troel, M.D. Jensen "Mechanisms of Neuropathic Pain" Pain 1996-An updated review, IASP Press SEATTLE (1996), p 77-86).

Chronic and/or neuropathic pains, remain the pain syndrome which are the most difficult to treat and there is a genuine need to develop novel active compounds.

For almost thirty years, very little progress has been made in the drug treatment of chronic pain and neuropathic pain and this remains restricted to the use of antidepressants, Nonsteroidal Anti-inflammatory drugs, local anesthetics, and anticonvulsants.

A number of anticonvulsants, such as valproate or carbamazepine, possess activity in the treatment of these pain conditions, but others such as pentobarbital are ineffective (H. L. Fields et al., Excitability Blockers, p93-116 - H. C. Hansen, MD "Treatment of chronic Pain With Antiepileptic Drugs: A New Era" South Medical Journal-Southern Medical Association (1999) 92(7) p 642-649).

Considerable precautions must be taken when using carbamazepine, which is a first line treatment, since the difference between the therapeutic dose and the dose inducing side effects is extremely small. Further, the posology inducing these effects varies depending on the patient. Thus the practitioner must be extremely vigilant when adjusting the doses to each individual treated. Side effects can include sedation, ataxia, dizziness, blurred vision, also nausea and vomiting. Further, about 10% of patients exhibit mild leukopenia (H. L. Fields et al., Excitability Blockers p 93-116).

Carbamazepine, which is the molecule in the antiepileptic category, which acts as a reference for pharmacological studies in the field of chronic or neuropathic pain, has a distinct activity in inhibiting artificially induced pain or hyperalgesia. However, pharmacological studies carried out by the Applicant have confirmed that the dose-activity curve does not only reverse the pain to the control threshold (reversal of hyperalgesia), but it goes beyond that and induces partial desensitization in treated subjects (alteration of normal threshold). Thus in the doses used therapeutically, an antinociceptive effect is observed and the animal no longer feels pain which it would feel in its normal state. Such desensitization can be particularly awkward as regards no-risk use by the patient. Thus if a patient who wanted to reduce chronic or neuropathic pain took too high a dose of carbamazepine, he would be exposed to partial desensitization. Thus with his sensitivity threshold being higher than normal, he would be much less receptive to any external aggressions such as heat, chafing or the like, and thus would risk injuring himself or burning himself.

The Applicant's pharmacological studies have revealed that levetiracetam behaves in an unexpected manner in the treatment of chronic or neuropathic pain. In contrast to carbamazepine, this molecule normalizes the dose/activity curve to the control pain threshold (i.e. response before induction of diabetes). Thus the use of levetiracetam has a very much higher safety margin of risk in the event of an overdose.

Further, in the therapeutic doses used, levetiracetam also has the advantage of being far removed from doses at which it is capable of inducing secondary effects while compounds such as carbamazepine have a greatly reduced safety margin.

This unexpected range of properties means that the use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide is of particular importance for the manufacture of a medicament for treatment and/or prophylactic treatment of chronic and/or neuropathic pain disorders.

The present invention requires administration of an effective dose of levetiracetam for the treatment and/or the prophylaxis of bipolar disorders, migraine and chronic or neuropathic pains. The dose required in accordance with the invention should be sufficiently high to permit the relief of bipolar disorders, migraine and chronic or neuropathic pains. Pharmaceutical compositions comprising levetiracetam can, for example, be administered orally or parenterally, i.e., intravenously, intramuscularly or subcutaneously, intrathecally.

Pharmaceutical compositions which can be used for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules, solutions, syrups, and the like.

To this end, levetiracetam can be used mixed with an inert diluent or a non-toxic pharmaceutically acceptable vehicle such as starch or lactose, for example. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as peppermint or methyl salicylate. They also comprise compositions which can release the active substance in a controlled manner. Pharmaceutical compositions which can be used for parenteral administration are in the pharmaceutical forms which are known for this mode of administration and are in the form of aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastic vials or infusion containers.

In addition to the active compound, these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiologic saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or

sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose.

5 These pharmaceutical forms are prepared using methods which are routinely used by pharmacists.

The percentage of active material in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of administration. Thus the quantity of active product in compositions for oral
10 administration is at least 0.5% by weight and can be up to 80% by weight with respect to the composition weight. The terms "active material" and "active product" as used by the Applicant mean levetiracetam alone or combined with at least one other pharmaceutically active compound for use in these pathologies. Non-limiting examples of these compounds which can be cited for use in combination with levetiracetam are
15 antivirals, antispasmodics (i.e.: baclofen), antiemetics, antimanic mood stabilizing agents, analgesics (i.e.: aspirin, ibuprofen, paracetamol), narcotic analgesics, topical anesthetics, opioid analgesics, lithium salts, antidepressants (i.e.: mianserin, fluoxetine, trazodone), tricyclic antidepressants (i.e.: imipramine, desipramine), anticonvulsants (i.e.: valproic acid, carbamazepine, phenytoin ...), antipsychotics (i.e.: risperidone, haloperidol),
20 neuroleptics, benzodiazepines (i.e.: diazepam, clonazepam), phenothiazines (i.e.: chlorpromazine), calcium channel blockers, amphetamine, clonidine, lidocaine, mexiletine, capsaicin, caffeine, quetiapine, serotonin antagonists, β -blockers, antiarrhythmics, triptans, ergot derivatives

For the preferred oral compositions, the dosage unit is in the range 50 to 3000
25 milligrams (mg) of active product.

In compositions for parenteral administration, the quantity of active material present is at least 0.5% by weight and can be up to 33% by weight with respect to the composition weight. For the preferred parenteral compositions, the dosage unit is in the range 1 mg to 400 mg of active product.

30 The daily dose can fall within a wide range of dosage units of active product, and is generally in the range 5 to 70 mg/kilogram (kg). However, it should be understood that the specific doses can be adapted to particular cases depending on the individual requirements, at the physician's discretion.

The efficacy of levetiracetam for the treatment of migraine, bipolar disorders and
35 chronic or neuropathic pains is illustrated by the results of the following pharmacological tests. These examples illustrate the invention without in any way limiting its scope.

EXAMPLE 1: Pharmacological data for the treatment of bipolar disorders.**Y maze test**

An increase in motor activity is a frequent symptom of manic disorders and as a
5 consequence, it is often used as a model of mania in laboratory animals. A wide variety of
compounds or combinations of compounds can cause hyperactivity; however, not all
forms of hyperactivity can be reversed by lithium. Further, not all activity tests are
suitable for observing reproducible hyperactivity.

Hyperactivity induced in rodents tested in a symmetrical "Y" maze by a mixture
10 of dexamphetamine and chlordiazepoxide (DEX-CDP) has been used by a number of
researchers to study the effect of lithium (Cox C. et al., *"Lithium attenuates 'manic'
activity in rats"* Nature (1971), vol. 232 p 336-338 - Vale A. L. and Ratchliffe F., *"Effect of
lithium administration on rat brain 5-hydroxyindole levels in a possible animal model of
mania"* Psychopharmacol. (1987), vol.91 p 352-355), or more recently the effect of the
15 antiepileptic "Valproate" (Cao B. J. and Peng N. A., *"Magnesium valproate attenuates
hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents"* Eur. J.
Pharmacol. (1993), vol. 237, p 177-181). Those two compounds have been used clinically
to treat bipolar disorders, i.e., acute mania and its management (see Gelenberg A. J. and
Hopkins H. S *"Report on efficacy of treatments for bipolar disorder"* Psychopharmacol.
20 Bull. (1993), vol. 29, p 447-456) and have significantly reduced hyperactivity induced by
DEX-CDP in rodents tested in a "Y" maze. Thus this model is acknowledged as a possible
animal model for the study of mania.

The efficacy of (S)-(-)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the treatment of
mania has thus been studied using the model described above, using rats in which
25 hyperactivity has been induced using the DEX-CDP mixture. Lithium and valproate were
also tested and used as reference compounds.

The animals used were male Sprague-Dawley rats (origin: OFA, IFFA, CREDO,
Belgium) weighing between 210 and 290 grams. They were placed in stainless steel cages
in groups of 8. The day prior to the experiment, they were placed in macrolon cages (4
30 animals per cage: 38 x 27 x 15 centimeters (cm)) with the floor covered with sawdust. The
cages were placed in an animal holding chamber provided with air conditioning,
illuminated from 0600 hrs to 1800 hrs. Food and water were available "ad libitum".

The apparatus used was a Y maze (each arm being 40 cm long and 15 cm wide
with 35 cm walls) constructed from grey Plexiglass, located in a faintly illuminated room
35 (Less than 5 Lux at ground level) and used to measure the rats' activity. The activity was
estimated by recording the number of entries into the arms of the maze over a five-
minute period. A video camera was positioned at a height of one meter above the

apparatus and connected to a monitor located in an adjacent room in which an experimenter counted the number of entries into the arms.

The injection of different compounds into the rats was performed under the following conditions. 12.5 mg/kg of chlordiazepoxide and 1.18 mg/kg of D-amphetamine sulfate were dissolved in a saline solution (0.9%) and administered simultaneously by subcutaneous injection 35 minutes before the test in a volume of 1 ml/kg. 17 and 54 mg/kg of levetiracetam were dissolved in a saline aqueous solution (0.9%) and injected intraperitoneally 30 minutes before the test (table 4). 50, 100 and 200 mg/kg of sodium valproate were dissolved in an aqueous saline solution (0.9%) and injected intraperitoneally 15 minutes before the test (table 2). 2 and 4 milliequivalents (meq) of Li^+ /kg of lithium chloride were dissolved in a saline solution (0.9%) and injected intraperitoneally 215 minutes before the test (table 1). The test drugs were injected in a volume of 5 ml/kg.

The effects of the different drugs were studied separately. In each experiment, the animals were placed in different groups ($n = 11$ or $13/\text{group}$) in a random fashion. During the test, each rat was placed in the center of the apparatus and the number of visits into the arms was recorded as an activity index.

For the results to be properly statistically analyzed, they were expressed as median with the first and third quartile. General comparisons of the statistics were carried out using a Kruskal-Wallis test for the controls and the effect of the compound *per se*. This test was also used to compare the effect of the (DEX-CDP) mixture, and the effect of the compounds against the hyperactivity induced by the (DEX-CDP) mixture.

In the event of a significant difference, multiple post hoc comparisons under the Kruskal-Wallis test were estimated using the method proposed by Siegel and Castellan (*Non parametric statistics*. McGraw Hill, second edition (1989)). Comparisons between the control group and the groups for the DEX-CPD mixture were carried out using the Mann-Whitney test (*Non parametric statistics*. McGraw Hill, second edition (1989)).

The results of these pharmacological studies are summarized and presented in Tables 1 to 4.

Administration of the DEX-CDP mixture induced a comparable and significant hyperactivity in each experiment.

Lithium chloride (table I) significantly counteracted the hyperactivity induced by DEX-CDP in a dose dependent manner. It even reduced the activity to below that of the non-hyperactive control rat. Lithium chloride *per se* induced a slight no significant reduction in the activity of non-hyperactive control.

Table I

	Treatment	Number of arms visited	P vs mixture	P vs control
	Control	26.5 (25.5-28)	0.0005**	—
5	Mixture	45 (39-48.5)	—	0.0005**
	Mixture + Lithium chloride 2 mEq/kg	31.5 (27-36)	NS	—
10	Mixture + Lithium chloride 4 mEq/kg	14 (10.5-17.5)	<0.001*	< 0.0001**
	Lithium chloride 2 mEq/kg	25 (21-26.5)	—	NS
15	Lithium chloride 4 mEq/kg	20 (16-23)	—	NS

Effect of lithium chloride on hyperactivity induced by a mixture of chlordiazepoxide and D-amphetamine in a Y-maze test. Results are expressed in terms of median with Q1 and Q3 in parentheses.

20 * Multiple comparison test under Kruskal Wallis;
** Mann-Whitney test; NS = no significant effect.
P = probability of the significant difference
P vs mixture = probability of the significant difference between the group tested and the mixture.

25 Sodium valproate (table II) significantly counteracted hyperactivity at a dose of 200 mg/kg. As was the case with lithium, sodium valproate tended to cause hypoactivity in the treated rats. Finally, it was observed that sodium valproate *per se* induced a strong dose dependent hyperactivity in non-hyperactive control.

30

Table II

	Treatment	Number of arms visited	P vs mixture	P vs control
5	Control	25 (24-28)	<0.0001**	—
	Mixture	43 (34-44)	—	<0.0001**
	Mixture + Sodium valproate 50 mg/kg	38 (36-41)	NS	—
10	Mixture + Sodium valproate 100 mg/kg	39 (32-41)	NS	—
	Mixture + Sodium valproate 200 mg/kg	20 (14-26)	<0.001*	0.06**
	Sodium valproate 50 mg/kg	28 (24-31)	—	NS
	Sodium valproate 100 mg/kg	34 (32-36)	—	<0.05*
	Sodium valproate 200 mg/kg	40 (28-43)	—	<0.01*

Effect of sodium valproate on hyperactivity induced by a mixture of chlordiazepoxide and D-amphetamine in a Y-maze test. Results are expressed in terms of median with Q1 and Q3 in parentheses. * Multiple comparison test under Kruskal Wallis; ** Mann-Whitney test; NS = no significant effect.

P = probability of the significant difference

P vs mixture = probability of the significant difference between the group tested and the mixture.

Levetiracetam (table III) significantly counteracted the hyperactivity induced by DEX-CDP at a dose of 54 mg/kg. Levetiracetam *per se* induced only a slight hyperactivity at a dose of 17 mg/kg.

Finally, an analysis of the experimental data showed a surprising normalization to the activity level of the non-hyperactive control rats when hyperactive rats (DEX-CDP) are treated with the highest dose of levetiracetam.

Table III

	Treatment	Number of arms visited	P vs mixture	P vs control
5	Control	25 (22-29)	<0.0001**	—
	Mixture	40 (36-48)	—	<0.0001**
	Mixture + Levetiracetam 17 mg/kg	36 (32-38)	NS	—
10	Mixture + Levetiracetam 54 mg/kg	26 (12-33)	<0.001*	NS
	Levetiracetam 17 mg/kg	31 (29-33)	—	<0.05*
	Levetiracetam 54 mg/kg	28 (26-28)	—	NS

15 Effect of levetiracetam on hyperactivity induced by a mixture of chlordiazepoxide and D-amphetamine in a Y-maze test. Results are expressed in terms of median with Q1 and Q3 in parentheses.

* Multiple comparison test under Kruskal Wallis;

** Mann-Whitney test; NS = no significant effect.

P = probability of the significant difference.

20 P vs mixture = probability of the significant difference between the group tested and the mixture.

Taken together, these results suggest that levetiracetam has an unexpected potential for the treatment of bipolar disorders.

EXAMPLE 2: Pharmacological data for treatment of chronic or neuropathic pain disorders.

In order to study the activity of levetiracetam as regards chronic or neuropathic pains, the Applicant carried out a series of experiments based on the Randall test "A method for measurement of analgesic activity on inflamed tissue; Arch. Int. pharmacodyn., 1957, CXI, No4. P 409-419". By virtue of this protocol, it was possible to determine the ability of levetiracetam to correct hyperalgesia secondary to induction of a neuropathic problem of metabolic origin in a rodent.

This study was performed with rats in which diabetes had been artificially induced by injecting streptozotocin. The diabetic neuropathy thereby induced allowed the correction of the hyperalgesia caused by the use of levetiracetam to be measured.

The animals used for these experiments were male Sprague-Dawley rats (Charles River, France), weighing 250-280 grams (g), which had undergone induction of diabetes one week after receipt. Male Sprague-Dawley rats (200-220 g) received one interperitoneal injection of streptozotocin (75 mg/kg, i.p.) (Zanosar®, Upjohn, France) dissolved in distilled water. Hyperglycaemia was confirmed one week after induction by determining the quantity of blood glucose (caudal puncture) using a Dextrostix reactive strip (Ames) read using a colorimeter (Ames Division, Miles Laboratoires, France). Animals with more than 14 millimoles (mM) were considered to be diabetic. The pain thresholds were determined 3 weeks after induction of diabetes. Only animals with a 15% reduction in the thresholds were selected.

This model was used in accordance with the description in COURTEX et al., "Streptozotocin-induced diabetic rats. Behavioural evidence for a model of chronic pain" Pain (1993), vol. 53, p81-88. The study was performed using the following compounds:

- LEVETIRACETAM: (Laboratoires UCB), dissolved in distilled water.
- CARBAMAZEPINE: (Sigma), dissolved in hydroxy propyl methylcellulose.

As has already been mentioned above, the test explained below was performed to stimulate a reaction in the animal with a mechanical nociceptive stimulus to a hind paw. An increasing pressure was applied using an analgesia meter (Ugo Basile, type 7200), until a cry was emitted which was considered to be the pain threshold, expressed in grams.

The experimental protocol and parameters measured are defined as follows.

After determining the base thresholds, the animals received the study treatments (vehicle, levetiracetam, 17, 54, 95.2 and 120 mg/kg, carbamazepine, 10 and 30 mg/kg) administered intraperitoneally (i.p.) using the equal block method to avoid any chronobiological influence. The effects of different treatments were thus determined during the same time period. The reaction thresholds were measured 15, 30, 45, 60, 90,

120 and 180 minutes (min) after administration. All of the experiments were performed blind with 8 different animals per treatment.

Table A : Performed treatments

5	Group	Test	No. of treated rats	Compound (mg/kg)	Dose	Administration	
						Route	Volume
10	1	Randall	56	Levetracetam	17; 54; 95.2; 120	i.p.	2ml/kg
		and					
15		Selitto	56	Carbamazepine Vehicle	10; 30		

No = number

i.p. = intraperitoneal

20

The results are expressed as means $\pm$ standard error of mean (S.E.M.). The areas under the curves as a function of time were calculated for each product using the trapezium method to obtain a picture of the overall effect. They were expressed as a variation of the vocalization thresholds with respect to the thresholds before injection.

25

The dose which could overcome 50% of the hyperalgesia induced by diabetes was calculated as the "anti-hyperalgesic dose effective 50".

30

Statistical comparison was carried out by means of a two-way analysis of variance followed by Fischer's PLSD multiple comparison test to analyze the temporal effect and using an unmatched sample Student test to compare the different treatments (areas under the curve).

By normal animal, the applicant means, animal in which no diabetes has been induced.

A study of the data obtained by the Applicant has revealed the following facts.

35

Induction of diabetes was accompanied by mechanical hyperalgesia, confirmed in all of the animals used by a significant reduction in the vocalization

~~2~~

thresholds from 309.4 ± 15.2 g to 152.8 ± 8.0 g. Injecting the vehicle did not significantly modify the vocalization thresholds (Table B).

TABLE B
EFFECT OF LEVETIRACETAM AND CARBAMAZEPINE ON HYPERALGESIA IN DIABETIC RATS

COMPOUNDS	BEFORE DIABETES	AFTER DIABETES							
		0 *	15	30	45	60	90	120	180
Vehicle	306.6 (10.93)	174.4 (4.19)	180.0 (2.83)	183.8 (4.70)	181.9 (5.97)	166.9 (3.40)	166.9 (5.97)	166.9 (5.26)	166.9 (4.43)
Levetiracetam 17 mg/kg	282.2 (5.48)	181.9 (3.09)	211.9 (7.19) *	206.3 (10.12) *	193.1 (7.19)	185.6 (4.86)	178.1 (3.40)	180.0 (2.83)	176.3 (2.45)
Levetiracetam 54 mg/kg	296.3 (10.12)	180.0 (5.30)	238.1 (22.04) *	243.8 (15.97) *	230.6 (14.44) *	189.4 (13.87)	176.3 (8.39)	176.3 (6.80)	176.3 (6.80)
Levetiracetam 95.2 mg/kg	306.6 (11.73)	169.7 (6.00)	264.4 (13.58) *	283.1 (24.62) *	234.4 (11.32) *	180.0 (12.36)	180.0 (8.02)	159.4 (3.95)	163.1 (4.43)
Levetiracetam 120 mg/kg	309.4 (15.25)	161.3 (7.23)	331.9 (31.75) *	315.0 (30.00) *	262.5 (27.04) *	213.8 (13.52) *	176.3 (7.36)	174.4 (6.30)	168.8 (4.70)
Carbamazepine 10 mg/kg	300.9 (12.31)	170.6 (5.26)	217.5 (18.59) *	333.8 (14.66) *	273.8 (12.60) *	206.3 (10.51) *	187.5 (8.02)	174.4 (3.95)	174.4 (3.95)
Carbamazepine 30 mg/kg	280.3 (9.92)	152.8 (8.01)	450.0 (44.10) *	425.6 (39.98) *	311.3 (36.05) *	230.6 (24.86) *	196.9 (14.01) *	174.4 (7.99)	170.6 (6.30)

Effect of Levetiracetam and Carbamazepine on vocalization threshold (g) in diabetic rats.
Results are expressed in terms of mean with SEM between brackets.
* = significant difference from controls (vehicle).
+ = time after injection of Levetiracetam and Carbamazepine (minutes).

In this test (Table B), a dose of 120 mg/kg of levetiracetam caused complete correction of hyperalgesia manifested by a statistically significant increase in the vocalization thresholds, at a maximum 15 min after injection, and persisting up to 60 min after injection. The increase in the thresholds observed with the 3 other doses was also significant from 15 minutes after injection up to 45 min for doses of 95.2 and 54 mg/kg and 30 min for the dose of 17 mg/kg. The anti-hyperalgesic effective dose 50 was 35.1 ± 1.8 mg/kg.

Carbamazepine used as the positive control caused a complete reversal of diabetic hyperalgesia for the 2 doses used (Table B). It became anti-hyperalgesic from fifteen minutes after injection of the dose of 30 mg/kg, an effect that persisted to the ninetieth minute.

The dose of 10 mg/kg only caused a reversal in hyperalgesia in the thirtieth minute after injection, the effect being maintained for sixty minutes.

These data also confirm that the active doses of carbamazepine altered the threshold of animals to a level above the level of normal animals (i.e. response before induction of diabetes), which could be detrimental to an adaptive pain feeling.

It should be noted that at a dose of 30 mg/kg, carbamazepine induced, with a delayed effect (30 min after injection), a reduction in spontaneous motor activity (which we did not quantify). Nevertheless, this could imply that at this dosage, carbamazepine has side effects like sedation, akinesia, or ataxia.

Taken together, these results suggest that levetiracetam has an unexpected potential as a drug for the treatment and or prophylactic treatment of chronic or neuropathic pains.

EPO-Munich
53

22

E2 11.09

Claims.

1. Use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or prophylactic treatment of bipolar disorders.
- 5 2. Use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or prophylactic treatment of migraine disorders.
3. Use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for
10 treatment and/or prophylactic treatment of chronic and/or neuropathic pain disorders.

EPO-Munich
53

- 7. Dez. 1999

[Handwritten signature]

Abstract

A use of (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment and/or prophylactic treatment of bipolar disorders, migraine, chronic and/or neuropathic pains is described.

EPO-Munich
53

- 7. Dez. 1999

EPO-Munich
53

7. De.

89 82 2

TRADUCCIÓN DEL INGLÉS AL CASTELLANO de las reivindicaciones contenidas en la Solicitud de Patente Europea No. 99124269.4 relacionada con:

USO DE (S)-(1)-ALFA-ETIL-2-OXO-1-PIRROLIDIACETAMIDA PARA EL TRATAMIENTO DE DESORDENES BIPOLARES Y DE DOLOR

ANEXOS: La Solicitud de Patente Europea arriba mencionada No. 99124269.4; Certificación del Presidente de la Oficina Europea de Patentes.

Texto en Inglés, Alemán y Francés

Oficina Europea de Patentes

Los documentos anexos son copias exactas de la solicitud Europea de Patentes descrita en la página siguiente, tal como fue originalmente presentada.

Solicitud de Patente No. 99124269.4

Por el Presidente de la Oficina Europea de Patentes

**(Firma Ilegible)
I.L.C.HATTEN-HECKMAN**

LA HAYA, el 26/10/00

SELLO ADHERIDO

Oficina Europea de Patentes

Hoja 2 del Certificado

Solicitud No. 99124269.4

Fecha de Presentación: 01/12/99

**Solicitante(s):
UCB, S.A.
1070 Bruselas
BÉLGICA**

Título de la Invención:

90 2 ~~65~~ 3

uso de (s)-(1)-alfa-etil-2-oxo-1-pirrolidiacetamida para el tratamiento de
desordenes bipolares y de dolor

Prioridad(es) reivindicada(s)

País:

Fecha:

Número de Presentación:

Clasificación Internacional de Patentes
AG1K31/40

Estados Contratantes designados a la fecha de presentación:
AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE

Notas:

Ver título original en la página 1 de la descripción

USO DE (S)-(1)-ALFA-ETIL-2-OXO-1-PIRROLIDIACETAMIDA PARA LA PREPARACIÓN DE UNA DROGA

REIVINDICACIONES

1. Uso de (s)-(1)-alfa-etil-2-oxo-1-pirrolidiacetamida para la fabricación de un medicamento para el tratamiento y/o tratamiento profiláctico de desordenes bipolares.
 2. Uso de (s)-(1)-alfa-etil-2-oxo-1-pirrolidiacetamida para la fabricación de un medicamento para el tratamiento y/o tratamiento profiláctico de desordenes de migraña.
 3. Uso de (s)-(1)-alfa-etil-2-oxo-1-pirrolidiacetamida para la fabricación de un medicamento para el tratamiento y/o tratamiento profiláctico de desordenes crónicos y/o desordenes de dolor neuropático.
-

Extracto

Se describe un uso de (s)-(1)-alfa-etil-2-oxo-1-pirrolidiacetamida para la fabricación de un medicamento para el tratamiento y/o tratamiento profiláctico de desordenes bipolares, migraña, de desordenes crónicos y/o desordenes de dolor neuropático.

ES TRADUCCIÓN FIEL Y COMPLETA DE LAS
REIVINDICACIONES CONTENIDAS EN EL DOCUMENTO ANEXO
TERMINADA ESTE 2 DE MARZO, 2001.

91 83664 ~~941~~



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99123803.1

**Der Präsident des Europäischen Patentamts:
Im Auftrag**

For the President of the European Patent Office

**Le Président de l'Office européen des brevets
p.o.**

I.L.C. HATTEN-HECKMAN

**DEN HAAG, DEN
THE HAGUE, 26/10/00
LA HAYE, LE**



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

92

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°: **99123803.1**

Anmeldetag:
Date of filing:
Date de dépôt: **01/12/99**

Anmelder:
Applicant(s):
Demandeur(s):
UCB, S.A.
1070 Bruxelles
BELGIUM

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Composition of levetiracetam and other compound, and therapeutic uses thereof

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
A61K31/55, A61K31/51, A61K31/56, A61K31/40

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: **AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LU/LV/MC/NL/PT/SE**
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

See for original title page 1 of the description

99123803.1

1

Composition of levetiracetam and therapeutic uses

This invention relates to new pharmaceutical compositions comprising levetiracetam and at least one compound inducing neural inhibition mediated by the GABA_A receptors.

The present invention is directed more specifically to a new pharmaceutical composition and their use for the treatment of epilepsy and for controlling seizures. Another aspect of this invention concerns the use of said composition for the treatment of bipolar disorders, migraine, major depressive disorders, and any other disease that could be treated with an effective but high amount of a compound inducing neural inhibition mediated by the GABA_A receptors, such as valproic acid or pharmaceutical acceptable salts thereof, and clonazepam, chlorthalidopride and phenobarbital alone, with reduced amount of this compound.

Valproic acid, prodrugs and pharmaceutically acceptable salts (sodium valproate, semi-sodium valproate, valpromide, valproate pivoxil...) are antiepileptic agents used in the monotherapy treatment of various forms of epilepsy and other seizure disorders. Valproic acid is considered as a first line drug in the treatment of generalised seizures, especially absence, tonic-clonic seizures and myoclonic seizures. Furthermore, it is often used for the treatment of simple and complex partial seizures with or without secondary generalization. Moreover, valproic acid, generally as semi-sodium valproate, is a recognised treatment of depression, particularly bipolar disorders. Valproic acid and derivatives may also be of value in treatment or prevention of migraine, muscle spasm, Hiccup and psychiatric disorders (Martindale, 1996; Davis L.L. & al., Psychopharmacol. Bull. (1996), 32, 647-652).

Valproic acid that could be used for the treatment of the precited pathologies, are characterized by a small therapeutic margin, and several adverse effects are reported with currently used therapeutic doses. The most frequently reported adverse effects associated with therapy with valproic acid or derivatives are gastro-intestinal disturbances, particularly on initiation of treatment. Less common adverse effects include increased appetite and weight gain, transient hair loss, tremor, drowsiness, ataxia, confusion, headache, reversible prolongation of bleeding time and thrombocytopenia.

For the treatment of epilepsy, the recommended initial dose of valproic acid for an adult in Europe is 600 mg/day, increasing at 200 mg at three-day intervals until seizure control is achieved or adverse effects preclude further increases. The usual range is 1 to 2 g daily (20 to 30 mg per kg body weight per day), with a maximum daily dosage of 2.5 g. The daily dosage recommended for children weighing more than 20 kg is 20 to 30 mg/kg/day. In children weighing less than 20 kg, a dosage of 20 mg/kg/day is recommended; in case of required dosage above 40 mg/kg/day, clinical chemistry and haematological parameters should be monitored. For elderly, dosage requirements of valproic acid should be lower

because of variations of pharmacokinetic parameters. For most patients, therapeutic plasma valproic acid concentrations will range from 40 to 100 µg/ml.

Barbiturates and benzodiazepines which enhance inhibitory GABA_A-ergic neurotransmission have broad spectrum anti-epileptic agents but are associated with very marked sedation ataxia and deficits in cognitive function at therapeutic doses. Benzodiazepines are effective in man against both primary generalized and partial seizures, other childhood epilepsies, and status epilepticus. Undesirable side effects are described such as the development of dependence and the possibility of withdrawal seizures, and include impairment of psychomotor skills, sedation, potentiation of alcohol effects, and amnesia.

Levetiracetam or (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide is disclosed in European Patent EP 162 036 as well as its use as a protective agent for the treatment and the prevention of hypoxic and ischemic type aggressions of the central nervous system. This compound is also effective in the treatment of epilepsy, a therapeutic indication for which it has been demonstrated that its dextrorotatory enantiomer (R)-(+)-α-ethyl-2-oxo-1-pyrrolidineacetamide completely lacks activity (Gower A.J. & al., Eur. J. Pharmacol. (1992), 222, 193-203). Recent results from three double-blind placebo controlled studies demonstrate that levetiracetam is an effective and well tolerated adjunctive agent in the treatment of refractory partial onset seizures (Shorvon S.D. et al., Epilepsia (1999) 40, Suppl. 7:76). Moreover, European Patent Application EP 645 139 discloses the use of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide for the treatment of anxiety, whereas the enantiomer (R)-(+)-α-ethyl-2-oxo-1-pyrrolidineacetamide do not possess any anxiolytic activity.

Animal safety studies with levetiracetam show no cardiovascular, carcinogenic, or reproductive toxicity. Signs of limited neurotoxicity occur in the form of slight sedation at very high doses. Otherwise, this compound is well tolerated. Clinical studies on healthy volunteers showed that levetiracetam is well tolerated at single dose (from 500 mg to 5.000 g) and repeated doses (1500 mg/day for 14 days). Preliminary data from tolerability studies suggest good tolerability in epileptic patients of doses up to 4000 mg/day.

Monotherapy, i.e. the treatment of epilepsy with a single antiepileptic drug, is the universally accepted regimen of choice for patients with newly diagnosed epilepsy. In approximately 70 % of these patients, administration of a single antiepileptic drug leads to complete seizure control without adverse effects. Unfortunately, monotherapy fails, even at maximal tolerated doses, in an important minority of patients (20 to 30 % of patients will not attain acceptable control with monotherapy) and, in these cases, polytherapy (i.e. adding a second drug, and more if necessary) is a common practice.

The aim of polytherapy is to identify polydrug regimens that have minimal adverse effects and maximal efficacy in clinical practice. But addition of a second (or even a third)

drug as part of combination therapy is often associated with a higher incidence of adverse events and greater toxicity. This is frequently due to pharmacokinetic modifications. For example, valproic acid displaces phenytoin from plasma proteins, significantly increasing its unbound fraction, inhibiting its metabolism and reducing its intrinsic clearance.

5 Valproic acid inhibits both the p-hydroxylation and the N-glucosidation of phenobarbital and significantly reduce its metabolic and total clearance. Valproic acid interferes also with the pharmacokinetic of carbamazepine, of lamotrigine and of felbamate (Riva R. & al., Drug Interactions (1996), 81, 470-493).

10 Accordingly, there is a need in the field for the development of pharmaceuticals that would cause as few and as mild toxic and side effects as possible and yet be effective against a wide variety of seizure types.

15 It has now been discovered that levetiracetam potentiates the anticonvulsant, and the anti-manic activity of compounds inducing neural inhibition mediated by GABA_A receptors without exacerbating related side effects. As a result of these unexpected pharmacological properties, patients obtaining control of their symptoms at the expense of marked adverse effects during monotherapy treatment with these compounds may obtain a significant improvement in their treatment outcome by combined dosing with a minor dose in combination with levetiracetam.

20 The present invention is related to the unexpected fact that levetiracetam, known as an antiepileptic compound, is an effective potentiating agent of the anticonvulsant, and the anti-manic activity of valproic acid and pharmaceutically acceptable salts thereof, clonazepam, chlorthalidone and phenobarbital.

25 Thus, the present invention concerns a pharmaceutical composition comprising levetiracetam and at least one compound inducing neural inhibition mediated by the GABA_A receptors.

By a compound inducing neural inhibition mediated by the GABA_A receptors, we understand the following compounds: benzodiazepines, barbiturates, steroids, and valproic acid or pharmaceutical acceptable salts thereof.

30 Benzodiazepines include the 1,4 benzodiazepines, such as diazepam and clonazepam, and the 1,5 benzodiazepines, such as clobazam. Preferred compound is clonazepam.

Barbiturates include phenobarbital and pentobarbital. Preferred compound is phenobarbital.

35 Preferred compounds used in the pharmaceutical composition of the invention are valproic acid, valpromide, valproate pivoxil, sodium valproate and semi-sodium valproate, and more preferably sodium valproate.

The amount of the active ingredients (levetiracetam and compound inducing neural inhibition mediated by the GABA_A receptors) in the pharmaceutical composition of the invention will vary depending on the mammal to which the compositions are administered.

the disease to be treated, other active ingredients present, etc. Generally, the amount of the compound inducing neural inhibition mediated by the GABA_A receptors and the amount of levetiracetam for a given composition and dosage form can be readily determined employing routine procedures.

5 The pharmaceutical composition of the present invention comprises an effective therapeutic amount of the compound inducing neural inhibition mediated by the GABA_A receptors, and an effective therapeutic amount of levetiracetam preferably in a ratio between 2 and 15.

10 The pharmaceutical compositions according to the present invention can be administered orally or parenterally.

The pharmaceutical compositions which can be used for oral administration may be solid or liquid, for example in the form of tablets (coated or uncoated), pills, dragees and gelatine capsules. Solid pharmaceutical compositions according to the present invention may be prepared according to conventional methods used by pharmacists. For this
15 purpose, the active compounds can be mixed with an inert diluent or a pharmaceutically acceptable non-toxic carrier, such as for example starch or lactose. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, a disintegrating agent, a lubricant, a sweetening agent such as sucrose or saccharine, a coloring agent or a flavoring agent. These compositions also include compositions that
20 allow controlled release of the active substances. Oral forms may be solutions, suspensions and syrups.

Similarly, the compositions which can be used for parenteral administration, for example aqueous solutions suspensions or emulsions, may be prepared according to conventional methods used by pharmacists. The active compounds can be dissolved in a
25 suitable pharmaceutically acceptable injectable carrier liquid.

Compositions comprising an elevated dose of levetiracetam present some interest: the protection against seizures may be higher than the protection obtained with levetiracetam alone. Compositions comprising a reduced dose of valproic acid present also some interest.

The compositions of the present invention may be used for the treatment of epilepsy and
30 for controlling seizures, for the treatment of depression, in particular bipolar disorders, and for the treatment of migraine and other diseases controlled with the compound inducing neural inhibition mediated by the GABA_A receptors. The daily effective dosage required depends on the condition being treated and on the individual characteristics of the patient.

In the pharmaceutical compositions of the present invention, the amount of
35 levetiracetam is at least sufficient to potentiate the aimed activity of the compound inducing neural inhibition mediated by the GABA_A receptors.

The pharmaceutical composition of the present invention have a good activity but reduced adverse events compared to the use of the compound inducing neural inhibition mediated by the GABA_A receptors, such as valproic acid alone, for controlling seizures.

The present invention concerns also a use of the pharmaceutical composition for the treatment of a disease.

By disease, we understand epilepsy, alcohol withdrawal, tremor, bipolar disorder, mania, obsessive compulsive disorder, panic disorder, anxiety and anxiety disorders, depression, migraines, headache, pain disorders, ischemia and head trauma.

The present invention concerns also a method for treatment of a human patient by using the pharmaceutical composition.

The present invention concerns also the pharmaceutical composition for use as a medicament for curing the said disease.

The present invention concerns also the use of the pharmaceutical composition for the manufacture of a medicament for a therapeutic application in the said disease.

The present invention concerns also a method for manufacturing a medicament intended for therapeutic application in the said disease, characterized in that the pharmaceutical composition is used.

The present invention is also directed to methods of treating humans to alleviate disease by the administration of the pharmaceutical composition

It is demonstrated that levetiracetam possess the ability to effectively potentiate valproic acid, clonazepam, chlorthalidone and phenobarbital in pharmacological models. The potentiating effect of levetiracetam permit the amount of valproic acid or pharmaceutically acceptable salts thereof to be reduced, and therefore the adverse events related to a valproic acid therapy to be reduced. Thus, patients obtaining an improvement of their symptoms at the expense of marked adverse effects during monotherapy treatment with valproic acid may obtain a significant improvement in their treatment outcome by combined dosing with a minor dose of valproic acid and levetiracetam. The same is the case for treatment with clonazepam, chlorthalidone and phenobarbital.

The potentiating effect of levetiracetam for valproic acid was evaluated in two different animals models of epilepsy: the sound-sensitive mice, a model of generalized epilepsy, and amygdala-kindled rats, a model of partial complex seizures with secondary generalization. The impairment of performance within the rotarod test was also measured. Levetiracetam appears to potentiate the seizure protection obtained with valproic acid, clonazepam, chlorthalidone and phenobarbital, but not the adverse effects associated with valproic acid, clonazepam, chlorthalidone and phenobarbital.

Bipolar affective disorders (or manic-depressive illness) are characterized by alternating episodes of depression, accompanied by psychomotor retardation, loss of appetite and sleep disturbances, and manic behavior which is characterized by hyperactivity, pressured

speech, hyperphagia and hypersexuality. Chemical and electrical kindling of seizures, which elicit long-term and oscillatory changes in neuronal excitability, may serve as a model for rapid-cycling manic-depressive disorders (Post R.M. & al., *Advances in Neurology* (1991), Eds Smith D., Treiman D., Trimbale M., Raven Press. Ltd., Vol.55, 239-277). Another model of mania used to evaluate drug activity consists in an animal model of hyperreactivity induced by a mixture of dexamphetamine and chlorthalidone in rodents. This model was used to evaluate the antimanic properties of levetiracetam and valproic acid, taken alone or in combination, and underlined a synergistic effect between the two drugs.

The use of a combination therapy may be associated with an altered response and/or a higher incidence of adverse events and greater toxicity due to a modification of plasma and brain levels of drugs, i.e. a modification of pharmacokinetic parameters. A pharmacokinetic study realized with valproic acid, diazepam and phenobarbital alone or in combination with levetiracetam have shown a constant brain/plasma ratio. This demonstrates that the synergistic effect observed in pharmacological models between valproic acid, clonazepam, chlorthalidone and phenobarbital together with levetiracetam is not due to pharmacokinetic factors.

The administration of the pharmaceutical composition of the invention results in an improved reduction in the frequency and severity of diseases. The incidence of unwanted side effects can be reduced by the pharmaceutical composition of the invention in comparison to using higher doses of a compound inducing neural inhibition mediated by the GABA_A receptors treatment to achieve a similar therapeutic effect.

Example 1: Interaction between levetiracetam and valproate in preventing audiogenic-induced clonic convulsions in and evaluation of the adverse effects with the rotarod test.

The purpose of this study was to evaluate the effect of levetiracetam on the anticonvulsant potency of valproate in sound sensitive mice, a genetic animal model with reflex seizures. In this model of generalized epilepsy, seizures can be evoked without electrical or chemical stimulation and seizure types, at least in part, are similar in their clinical phenomenology to seizures occurring in man (Löscher W. & Schmidt D., *Epilepsy Res.* (1988), 2, 145-181; Buchhalter J.R., *Epilepsia* (1993), 34, 831-841).

Male genetically sound-sensitive mice (15 - 20 g; N=10), derived from a DBA strain originally selected by Dr Lehmann of the Laboratory of Acoustic Physiology (Paris) and bred in the UCB Pharma Sector husbandry unit since 1978, were submitted on one hand to the induction of audiogenic seizures, and on the other hand to a rotating rod test. The experimental design consisted of one group receiving vehicles, another group receiving levetiracetam alone at a dose of 5.5 mg/kg and the other groups receiving different doses of valproate alone or in combination with levetiracetam. Levetiracetam alone was also tested.

Levetiracetam and valproate, in a dose-volume of 10 ml/kg body weight, were administered intraperitoneally 60 and 30 minutes, respectively, before the induction of audiogenic seizures or the measurement of rotarod performance. Levetiracetam and sodium valproate were both dissolved in 0.9 % saline solution, to give solutions of pH 6.4 and 6.2, respectively.

For audiogenic seizure testing, the mice were placed in the cages, one mouse per cage, in the sound-attenuated chamber. After a period of habituation of 30 seconds, the acoustic stimulus (90 dB, 10 - 20 kHz) was delivered for 30 seconds via the loud speakers. During this interval, the mice were observed and the presence of the 3 phases of the seizure activity, namely wild running, clonic and tonic convulsions, was recorded. The proportion of mice protected against clonic convulsions was calculated and used as the end point for the anticonvulsant activity.

For rotarod testing, the mice were placed on the rotating rod and the animals that were unable to remain on the rod for at least 60 seconds were considered as having an impaired performance.

Methods used for calculation and statistical analysis are described hereafter:

- A response to drug treatment was expressed as the proportion of animals protected against induced convulsions, or showing an impairment of the rotarod performance, at each individual dose. When similar doses of the same compound were tested in independent experiments, their results were (Chi-Square test for homogeneity of proportions) and combined in case of non significance ($P > 0.05$).
- Dose-response curves of individual compounds were fitted in the form of a LOGIT - LOG DOSE linear weighted regression. A Chi-Square test of goodness of fit was used to assess adequacy of the fitting procedure.

When the dose of levetiracetam associated with valproate was considered as inactive by itself, an ordinary LOGIT-LOG DOSE regression as above was fitted. If the dose of levetiracetam has been proved to be active by itself, the observed proportions for mixtures were corrected by subtracting the effect due to levetiracetam by following principally the Abbott's method (Roberts M. & Boyce C.B.C., Methods in Microbiology (1972), Eds. Norris J.R. & Ribbons D.W. Academic Press. Vol 7A, 153-188) and the Bartholomew's method (Fleiss J.L., Statistical methods for rates and proportions. 2nd edition (1981), Eds. Wiley J. and Sons).

- Two theoretical models of interaction were used to evaluate the combined effects of valproate and levetiracetam: the additive model and the independent model. Effects will be defined as additive when replacement of part of the dose of one drug by another, in an amount proportionate to the relative potency of the drugs, maintains the same effect (Plummer J.L. & Short T.G., J. Pharmacol. Methods (1990), 23, 287-308). The independent model is based on different modes of action for the two drugs (Chou T.C. &

Talaky P., Adv. Exp. Regul. (1984), 22, 27-55). In these models, a difficulty arises when the slopes (the HILL-like coefficients) of the dose-response curves are different. However, by applying the median-effect principle, which forms the theoretical basis of the models, it may be shown that in the restricted condition, where $p = 0.5$ (50 % protection), the value of the slopes can be ignored. The derived formulation of the theoretical models are:

$$\frac{V_{m50}}{V_{50}} + \frac{L_{m50}}{L_{50}} = 1 \text{ for the additive model,} \quad \frac{V_{m50}}{V_{50}} + \frac{L_{m50}}{L_{50}} + \frac{V_{m50} \times L_{m50}}{V_{50} \times L_{50}} = 1$$

for the independent model,

where V_{m50} and L_{m50} are the doses of valproate and levetiracetam, respectively, in a mixture that should result in a 50 % protection; V_{50} and L_{50} are the ED_{50} values of valproate and levetiracetam, respectively, when tested alone. From these formulations, the dose of valproate, considered as expected value, that should be associated to a constant dose of levetiracetam in order to afford 50 % of protection, may be calculated as :

$$V_{m50} = V_{50} \times \left(1 - \frac{L_{m50}}{L_{50}}\right) \text{ for the additive model} \quad V_{m50} = V_{50} \times \left(\frac{L_{50} - L_{m50}}{L_{50} + L_{m50}}\right)$$

for the independent model

These calculated doses (V_{m50} expected) may then be compared to the observed doses of valproate which, in combination with a constant dose of levetiracetam, induce an effect corresponding to 50 % protection (V_{m50} observed). In case of a supra-additive effect, the ratio V_{m50} expected/ V_{m50} observed is greater than 1 and may be considered as a measure of the reduction of the dose of valproate, in presence of levetiracetam, needed to afford 50 % protection.

- An alternative approach, the "non-parallel dose-response curves method" (Plummer J.L. & Short T.G., J. Pharmacol. Methods (1980), 23, 297-308), which does not restrict the comparison of observed and predicted responses to the particular condition defined by $p = 0.5$ and takes into account the different slopes of the individual dose-response curves of the two compounds to be combined, was also employed. Accordingly, expected responses were calculated for each tested mixture of valproate and levetiracetam and compared to observed responses, a comparison from which a diagnosis of the type of interaction (additivity - supra-additivity - antagonism) may be proposed for various levels of effects and doses. Where the number of dose combinations tested was high enough, a rough statistical test was used to assess significance of the results based upon the proportion of mixtures showing consistent directional divergences between observed and expected responses (Two-sided Binominal Test considering random positive and negative differences between observed and expected results as null hypothesis).

Audiogenic seizure testing results are as follows :

- The estimated parameters from the linearized LOGIT - LOG DOSE regression are presented in table xxi.

[Handwritten signature]

	Valproate	Levetiracetam
ED ₅₀ (mg/kg)	122	10
Slope	4.29	2.28

Table xx1

- 5 - From the dose-response relation adjusted to the results of levetiracetam alone, it was inferred that the dose of 5.5 mg/kg of levetiracetam has a significant activity by itself 20 % of animals are protected by this dose. This proportion was taken into account for correcting the observed proportions of protected animals with mixtures, as explained above. The dose of valproate, in combination with 5.5 mg/kg of levetiracetam, able to afford protection against audiogenic-induced clonic convulsions in 50 % of the animals was estimated from the resultant adjusted curve: Vm₅₀ observed = 3.9 mg/kg
- 10 - Results obtained from the additive and the independent theoretical models of interaction are presented in table xx2 and may be interpreted as supra-additive interaction. A nine to fourteen reduction of the valproate dose needed to protect 50 % of the animals against audiogenic-induced clonic convulsions was obtained in the presence of levetiracetam. This result may be interpreted as a supra-additive interaction.
- 15

	Vm ₅₀ expected	Vm ₅₀ observed	$\frac{Vm_{50} \text{ expected}}{Vm_{50} \text{ observed}}$
Additive model	54.9	3.9	14.1
Independent model	35.4	3.9	9.1

Table xx2

Impairment of performance within the rotarod test is as follows :

- 25 - The estimated parameters from the linearized LOGIT-LOG DOSE regression are presented in table xx3.

	Valproate	Levetiracetam
ED ₅₀ (mg/kg)	178.5	360.7
Slope	2.21	0.77

Table xx3

- 30 - From the dose-response relation adjusted to the results of levetiracetam alone, it was inferred that the dose of 5.5 mg/kg of levetiracetam has a slight activity by itself: 4 % of animals showed an impairment of the rotarod performance. This proportion was taken into account for the fitting of a curve relating the response to valproate doses associated to levetiracetam in the form of a LOGIT-LOG DOSE. From this adjusted curve, dose of
- 35

valproate, in combination with 5.5 mg/kg of levetiracetam, able to produce an impairment of the rotarod performance in 50% of the animals was estimated :

VM_{50} observed = 127.5 mg/kg

- 5
- The values VM_{50} expected were calculated according to the additive and the independent theoretical models, and were compared to the corresponding observed doses of valproate (table xxi4). A slight reduction of the valproate dose needed to produce an impairment of the rotarod performance in 50 % of the animals was obtained in the presence of levetiracetam, a result that may suggest a modest supra-additive interaction.

10

	VM_{50} expected	VM_{50} observed	$\frac{VM_{50} \text{ expected}}{VM_{50} \text{ observed}}$
Additive model	175.8	127.5	1.38
Independent model	178.1	127.5	1.38

Table xxi4

15

Conclusions are as follows :

- This study reveals an unexpected, supra-additive interaction in the protection afforded by combined dosing with valproate and levetiracetam against audiogenic-induced clonic convulsions in sound-sensitive mice. A minor supra-additive interaction cannot be excluded in the impairment of performance within the rotarod test but this interaction clearly appears more discrete as shown by the ratio VM_{50} expected/ VM_{50} observed in the following table (table xxi5).
- 20

25

		Audiogenic seizure testing	Rotarod test
$\frac{VM_{50} \text{ expected}}{VM_{50} \text{ observed}}$	additive model	14.1	1.4
$\frac{VM_{50} \text{ expected}}{VM_{50} \text{ observed}}$	independent model	9.1	1.4

Table xxi5

- 30
- The therapeutic ratio of valproate within sound-sensitive mice is low due to a minimal separation in the doses protecting against sound-induced clonic convulsions (ED_{50} = 122 mg/kg) and impairing the rotarod performance (TD_{50} = 178 mg/kg). However, the supra-additive interaction in the protective effect against clonic convulsions and the minor interaction observed within the rotarod test enables consistent seizure protection
- 35
- after combined dosing with valproate and levetiracetam with the advantage that the dose

of valproate, and thereby the impairment obtained within the rotarod test, can be reduced markedly (table xxb).

Treatment inducing protection within 50 % of the sound-sensitive mice against audiogenic induced clonic convulsions.	Impairment in the performance within the rotarod test obtained after the same-treatment.
Valproate (122 mg/kg) + saline	30 %
Valproate (3.9 mg/kg) + levetiracetam (5.5 mg/kg)	< 0.1 %

Table xxb

Similar experiments were performed in order to evaluate the interaction between levetiracetam and other GABAergic agents, namely clonazepam, chlordiazepoxide and phenobarbital.

Levetiracetam potentiated the anticonvulsant activity afforded by clonazepam, chlordiazepoxide and phenobarbital in sound-sensitive mice. The dose needed to protect 50% of the animals against audiogenic-induced clonic convulsions was significantly reduced when combining 5.5 mg/kg of levetiracetam with clonazepam (reduced by a factor of 4.5 to 7.0), chlordiazepoxide (reduced by a factor of 3.7 to 5.8) and phenobarbital (reduced by a factor of 3.5 to 5.5). This supra-additive interaction was not associated with a similar increase in adverse effects potential. As for valproate, the impairment of rotarod performance induced by clonazepam, chlordiazepoxide and phenobarbital was not affected by combined treatment with a dose of 5.5 mg/kg levetiracetam.

Example 2: Interaction between levetiracetam and valproate in secondary generalized motor seizure in amygdala-kindled rats and evaluation of the adverse effects with the rotarod test.

The purpose of this study was to evaluate the pharmacodynamic interaction between valproate levetiracetam in preventing secondarily generalized motor seizures in amygdala-kindled rats, a model that has repeatedly been proposed to reflect complex partial seizures with secondarily generalization in man (Löscher W. & al., Exp. Neurol. (1986), 93, 211-226; McNamara J.O., Ann. of Neurol. (1984), 16 (suppl.), S72-S76).

In this model, focal electrical kindling of amygdala in rats induces the development of electrical seizure activity (afterdischarges) in amygdala and behavioral seizures, generally evolving through facial clonus, head nodding, forelimb clonus, rearing and fully kindled seizures with rearing and falling accompanied by generalized clonic seizures (Racine R.J., Electroencephalogr. Clin. Neurophysiol. (1972), 32, 281-294).

Kindling was induced in male Sprague Dawley rats (200-250g) by following the method described by Löscher (Löscher W. & al., Exp. Neurol. (1986), 93, 211-226).

Levetiracetam and valproate, in a dose-volume of 5 ml/kg body weight, were administered intraperitoneally 60 and 30 minutes, respectively, before the induction of kindling or the measurement of rotarod performance. Levetiracetam (17, 54 and 105 mg/kg) and sodium valproate (50, 100, 150, 200 and 300 mg/kg) were both dissolved in 0.9% NaCl to give solutions of pH 5.9 and 6.3, respectively. Control rats received an equivalent dose-volume of the appropriate vehicle.

For the kindling experiments, all kindled animals (n=8) were stimulated once with the same stimulation parameters as used for the induction of kindling, 60 and 30 minutes after intraperitoneal administration of saline. Two days later, drugs were tested. The behavioral effect of stimulation was graded according to the score of Racine (Racine R.J.,

Electroencephalogr. Clin. Neurophysiol. (1972), 32, 281-294). The proportion of rats protected against secondarily generalized motor seizures (a score of either 3, 4 or 5) was calculated for each group and used as end point for anticonvulsant activity.

The amygdala-kindled rats (n=8) were also tested on a rotating rod. The animals were pretreated with i.p. administrations of levetiracetam and valproate 60 and 30 minutes, respectively, before testing. Only animals that were unable to remain on the rod after three subsequent 1-minute attempts were considered as having an impaired performance. Results were analysed as described in example 1.

Protection against secondarily generalized motor seizures is as follows :

- The estimated parameters from the linearized LOGIT-LOG DOSE regression are presented in table xx7:

	Valproate	Levetiracetam
ED ₅₀ (mg/kg)	197	307
Slope	5.35	0.88

Table xx7

- From the dose-response relation adjusted to the results of levetiracetam alone it was inferred that each of these doses has a significant activity by itself. Calculated proportions of animals protected by these three doses of levetiracetam alone are 7, 18 and 28.5 %, respectively. These proportions were taken into account for correcting the observed proportions of protected animals with mixtures, as explained precedently. From the adjusted curves, the doses of valproate able to afford protections against secondarily generalized motor seizures in 50 % of the animals in the presence of 17, 54 or 105 mg/kg of levetiracetam, respectively, were estimated (table xx8).

13

	Vm ₅₀ observed (mg/kg)
Valproate + 17 mg/kg of levetiracetam	68.5
Valproate + 54 mg/kg of levetiracetam	27.5
Valproate + 108 mg/kg of levetiracetam	26.5

5 Table xx8

10 - Doses of valproate that affords protection against secondarily generalized motor seizures in 50 % of the animals when associated with constant doses of levetiracetam were calculated according to the additive and the independent theoretical models. Results of these calculations (Vm₅₀ expected) are presented in table xx9, where they are compared to the corresponding doses of valproate, observed to give 50 % protection when associated with levetiracetam (Vm₅₀ observed). A three to five fold reduction of the valproate dose needed to protect 50% of the animals may be obtained in the presence of levetiracetam, a result that may be interpreted as a supra-additive interaction.

15

	Additive model		Independent model	
	Vm ₅₀ expected	$\frac{Vm_{50} \text{ expected}}{Vm_{50} \text{ observed}}$	Vm ₅₀ expected	$\frac{Vm_{50} \text{ expected}}{Vm_{50} \text{ observed}}$
Valproate + levetiracetam 17mg/kg	188	2.7	176.4	2.6
20 Valproate + levetiracetam 54 mg/kg	182	5.9	138	5.0
Valproate + levetiracetam 108 mg/kg	127.8	4.8	94.6	3.5

Table xx9

25 Impairment of performance within the rotarod test is as follows :

30 - Valproate estimated parameters from the linear LOGIT-LOG DOSE regression are presented in table xx10. None of the three doses of levetiracetam tested (108, 170 and 540 mg/kg) impaired the performance of the amygdala-kindled rats in this test and the doses of levetiracetam used in combination with valproate (108 and 170 mg/kg) were therefore considered as inactive.

35

Valproate	
ED ₅₀ (mg/kg)	205
Slope	3.64

Table xx10

- Independent LOGIT-LOG VALPROATE DOSE regressions were fitted to the results obtained in the presence of these two constant doses of levetiracetam: 108 and 170 mg/kg. Parameters estimated from these fittings are reported in table xx11.

	VM_{50} observed [mg/kg]
Valproate + 108 mg/kg of levetiracetam	161
Valproate + 170 mg/kg of levetiracetam	174

Table xx11

- A slight leftward shift was observed in the dose-response curves when valproate was associated with levetiracetam. However, no consistent dose-related effects of levetiracetam was present, as could be anticipated with a drug inducing a supra-additive effect. A comparison of the VM_{50} values for valproate, estimated from these dose-response curves, substantiates this observation (205, 161 and 174 mg/kg for the 0, 108 and 170 mg/kg doses of levetiracetam combined with valproate).

Conclusions are as follows :

- This study reveals an unexpected, supra-additive interaction in the protection afforded by combined dosing with valproate and levetiracetam against the expression of secondarily generalized motor seizures in amygdala kindled rats. In contrast, no significant interaction was observed with regard to adverse effects quantified by performance within the rotarod test. The latter was to be expected since the doses of levetiracetam used were inactive themselves within this test.
- The therapeutic ratio of valproate within amygdala-kindled rats is limited with nearly identical doses resulting in protection against secondarily generalized motor seizures ($ED_{50} = 197$ mg/kg) and impairment in the rotarod test ($TD_{50} = 205$ mg/kg). However, the supra-additive interaction against the secondarily generalized motor seizures and the lack of any significant interaction within the rotarod test enables consistent seizure control after combined dosing with valproate and levetiracetam with the advantage that the dose of valproate, and thereby the impairment obtained within the rotarod test, can be reduced markedly (table xx12).

100
J

15

Treatment inducing protection within 50 %
of the amygdala-kindled rats against
the expression of secondarily generalized
motor seizures

Impairment in the performance within the
rotarod test obtained after the same
treatment

5	Valproate (197 mg/kg) + saline	48 %
	Valproate (68.5 mg/kg) + levetiracetam (17 mg/kg)	2 %
	Valproate (27.5 mg/kg) + levetiracetam (34 mg/kg)	< 0.1 %
10	Valproate (27 mg/kg) + levetiracetam (108 mg/kg)	< 0.1 %

Table xxi2

- On an other hand, the activity curve comparison of levetiracetam alone or in combination
with valproic acid leads to the conclusion that the use of a combination of the two drugs
is always interesting, even if levetiracetam high doses are employed. The dose effect curve
of levetiracetam is very small, that means that 100 % of animals could be protected
against induced-convulsions, but with very high doses of levetiracetam. The addition of a
small amount of valproic acid allows 100 % of animals to be protected with more
acceptable doses of levetiracetam

**Example 2: Attenuation of hyperactivity induced by a mixture of dexamphetamine-
chlordiazepoxide in the rat.**

The purpose of the present experiment was to study the effects of levetiracetam
administered alone or in combination with valproate on the hyperactivity induced in rats
by a mixture of dexamphetamine-chlordiazepoxide (DEX-CDP) evaluated in a Y-shaped
maze apparatus, a test recognized as a model for mania. Increased motor activity is a
frequent symptom of manic disorders and, therefore, is often used as a model of mania in
laboratory animals. Lithium, a medicine approved by the FDA in the prophylaxis and the
treatment of bipolar disorders and mania, and valproate, indicated for the treatment of
manic episodes associated with bipolar disorders, have been shown active in this model of
mania (Vale A.L. & Ratcliffe F., Psychopharmacol. (1987), 91, 352-355 ; Cao B.J. & Peng
N.A., Eur. J. Pharmacol. (1993), 237, 177-181).

Hyperactivity was induced in male Sprague Dawley rats weighing 210-290 g (n = 13 or
15 per group) by a mixture of dexamphetamine-chlordiazepoxide as described by Vale A.L.

(Vale A.L. & Ratcliffe F., Psychopharmacol. (1987), 91, 352-355). Chlordiazepoxide 12.5 mg/kg and D-amphetamine sulfate 1.18 mg/kg were dissolved in saline solution (0.9 %) and coadministered subcutaneously 35 minutes before testing in a volume of 1 ml/kg. Levetiracetam 17 mg/kg was dissolved in saline solution (0.9 %) and injected i.p. 30 minutes before testing. Sodium valproate 150 mg/kg was dissolved in saline solution (0.9 %) and injected i.p. 15 minutes before testing. The test drugs were injected in a volume of 5 ml/kg.

Each rat was placed in the center of the Y-maze (with each arm 40 cm long and 15 cm wide with 35 cm walls) constructed in gray plexiglas. The number of visits into the arms was recorded over a 5 minutes period as an index of activity.

The results were expressed as median with the first and third quartile. Overall statistical comparisons were made using the Kruskal Wallis test for the effect of the compounds per se on the one hand, and for the effect of the compounds against the mixture induced-hyperactivity on the other hand. In a case of a significant result, post hoc multiple comparisons under the Kruskal Wallis test were computed following the method proposed by Siegel and Castellan (Siegel S. & Castellan N.J., Non parametric statistics (1988), Mac Graw Hill, Second Edition). Comparison between control group and DEX-CDP mixture group was made using the Mann-Whitney test.

A possible interaction between levetiracetam and valproate against DEX-CDP induced hyperactivity was evaluated by combining inactive doses of levetiracetam (17 mg/kg) and sodium valproate (150 mg/kg) (table 2ax1). The combination between levetiracetam 17 mg/kg and valproate 150 mg/kg induced an important effect against the hyperactivity induced by the DEX-CDP mixture. The effect of the combination was statistically significant ($p < 0.05$) while effects of levetiracetam 17 mg/kg and valproate 150 mg/kg given alone were not different from effects observed in the group of animals administered with the mixture alone. The animals treated with the combination of levetiracetam and valproate were not different from the control animals not treated with the mixture.

17				
Treatment	n	Number of arms visited	p vs mixture	p vs mixture + Levetiracetam 17 + valproate 150
Control	13	23 (20-28)	<0.001**	NS**
5 Mixture (1)	13	48 (44-51)	-	<0.05*
Levetiracetam 17 mg/kg + Valproate 150 mg/kg +				
10 mixture (1)	13	18 (14-25)	<0.05*	-
Levetiracetam 17 mg/kg +				
mixture (1)	13	48 (41-49)	NS	<0.05*
Valproate 150 mg/kg +				
15 mixture (1)	13	41 (18-49)	NS	<0.05*

Table xax1 : Effect of levetiracetam and valproate on hyperactivity-induced by a mixture of chlordiazepoxide plus D-amphetamine in a Y-maze test. Results are expressed in terms of median with Q1 and Q3 in parentheses. * Multiple comparisons tests under Kruskal Wallis ; ** Mann-Whitney test. NS = not significant effect, P = probability of the significant difference, P vs mixture: probability versus DEX-CDP mixture (probability of the significant difference between the group tested and the mixture).

(1) : Mixture = DEX-CDE mixture.

Example 4 : Plasma and brain levels - Interaction between levetiracetam and valproic acid in preventing audiogenic seizure in mice.

The aim of this pharmacological study was to investigate possible interactions between levetiracetam and valproic acid.

Male genetically sound-sensitive mice (17 - 30 g; N=10), derived from a DEA strain originally selected by Dr Lehmann of the Laboratory of Acoustic Physiology (Paris) and bred in the UCB Pharma Sector husbandry unit since 1978, were submitted to the induction of audiogenic seizures. Levetiracetam (5.4 mg/kg) and sodium valproate (166.2 mg/kg) were administered orally, alone or in combination, 60 minutes before the induction of audiogenic

seizures. For testing audiogenic seizure, the mice were placed in the cages, one mouse per cage, in the sound-attenuated chamber. After a period of habituation of 30 seconds, the acoustic stimulus (90 dB, 10 - 20 kHz) was delivered for 30 seconds via the loud speakers. During this interval, the mice were observed and the presence of the 3 phases of the seizure activity, namely wild running, clonic and tonic convulsions, was recorded. In all animals, blood samples were collected immediately after the seizure test (1 h after dosing) by cardiac puncture under light carbon dioxide anesthesia, into heparinised microtubes. The samples were centrifuged at 12000 r.p.m. for 5 minutes and the separated plasma was transferred into polypropylene microtubes and stored frozen at -20°C. Whole brains were removed at the same time, frozen in liquid nitrogen and stored at -20°C. Half of these samples were used for the determination of levetiracetam concentrations, the other half for the determination of valproic acid concentrations. Levetiracetam was measured in plasma and brain samples by validated gas chromatography assay with mass detection. With sodium valproate, fluorescence polarization immunoassays were used.

15

	Method-detection	Limits of quantitation	
		plasma (µg/ml)	brain (µg/mg)
Levetiracetam	GC-MS	0.02	0.4
Valproic acid	FPIA	43.2	43.2

20 Table xc13

The mean value plus standard deviation was calculated for plasma and brain concentrations of valproic acid and levetiracetam, and for the brain/plasma ratio. The statistical analysis was performed using the statistical software STATGRAPHICS (5.1 version). Statistical differences between the control groups (levetiracetam or sodium valproate alone) and the test group were evaluated using the student's t-test. The normality of the distribution and the homoscedasticity were checked before using a parametric method. If it was not applicable, the Mann-Whitney U-test was used.

Levetiracetam plasma concentrations in sub-studies were approximately 4.3 µg/ml. Concentrations were not different when given alone or in combination with valproic acid. Brain concentrations were about 50 % of plasma concentrations. The brain /plasma ratio of levetiracetam was not modified when given in combination with valproic acid, that indicated the distribution profile (i.e. brain penetration) of levetiracetam was not change in the presence of valproic acid. A 33 % decrease of plasma concentrations (statistically significant) were obtained for valproic acid administered in combination with levetiracetam (table xc14). However, the brain/plasma ratio of valproic acid was not modified. It means, that the penetration of valproic acid was not modified by the coadministration of levetiracetam.

102
36

	Plasma (µg/ml)	brain (µg/g)	brain/plasma ratio
Valproate 188.2 mg/kg alone	222.5 ± 44.7	29.1 ± 8.2	0.13 ± 0.03
5 Valproate 188.2 mg/kg + levetiracetam 5.4 mg/kg	149.3 ± 32.4	21.1 ± 6.6	0.14 ± 0.03

Table xx14

10 Similar experiments were performed in order to evaluate a possible pharmacokinetic interaction between levetiracetam and other GABAergic agents, namely diazepam and phenobarbital.

15 Levettiracetam plasma concentrations were not different when given alone or in combination with phenobarbital. A 22% increase in plasma concentrations was obtained for levetiracetam administered in combination with diazepam. However, as for phenobarbital and valproic acid, the brain/plasma ratio of levetiracetam was not modified when given in combination with diazepam. This indicated that the distribution profile of levetiracetam was not changed in the presence of these compounds. Moreover, the plasma concentrations and brain/plasma ratio of diazepam and phenobarbital were unchanged when administered alone or in combination with levetiracetam, indicating
20 that the distribution profile of these compounds was not modified in the presence of levetiracetam.

CLAIMS

1. A pharmaceutical composition comprising levetiracetam and at least one compound inducing neural inhibition mediated by the GABA_A receptors.

2. The pharmaceutical composition of claim 1, characterized in that the compound inducing neural inhibition mediated by the GABA_A receptors is chosen among benzodiazepines, barbiturates, steroids, and valproic acid or pharmaceutical acceptable salts thereof.

3. The pharmaceutical composition of claim 2, characterized in that the benzodiazepines include the 1,4 benzodiazepines, such as diazepam and clonazepam, and the 1,5 benzodiazepines, such as clobazam.

4. The pharmaceutical composition of claim 2, characterized in that the barbiturates include phenobarbital and pentobarbital.

5. The pharmaceutical composition of claim 2, characterized in that the valproic acid or pharmaceutical acceptable salts thereof are chosen among valproic acid, valpromide, valproate pivoxil, sodium valproate and semi-sodium valproate.

6. The pharmaceutical composition of claim 5, characterized in that the compound inducing neural inhibition mediated by the GABA_A receptors is sodium valproate.

7. The pharmaceutical composition of claim 1, characterized in that it comprises an effective therapeutic amount of the compound inducing neural inhibition mediated by the GABA_A receptors, and an effective therapeutic amount of levetiracetam in a ratio between 2 and 15.

8. A use of the pharmaceutical composition of claim 1 for the treatment of disease chosen among epilepsy, alcohol withdrawal, tremor, bipolar disorder, mania, obsessive compulsive disorder, panic disorder, anxiety and anxiety disorders, depression, migraine, headache, pain disorders, ischemia and head trauma.

9. A use of the pharmaceutical composition of claim 1 for the manufacture of a medicament for a therapeutic application in a disease chosen among epilepsy, alcohol withdrawal, tremor, bipolar disorder, mania, obsessive compulsive disorder,

72

21

panic disorder, anxiety and anxiety disorders, depression, migraine, headache, pain disorders, ischemia and head trauma.

ABSTRACT**Composition of levetiracetam and therapeutic uses**

- 5 This invention relates to new pharmaceutical compositions comprising levetiracetam and at least one compound inducing neural inhibition mediated by the GABA_A receptors.

~~104~~
34/5

TRADUCCIÓN DEL INGLÉS AL CASTELLANO de las reivindicaciones contenidas en la Solicitud de Patente Europea No. 99123803.1 relacionada con:

COMPOSICIÓN DE LEVETIRACETAM Y OTRO COMPUESTO, Y SUS USOS TERAPÉUTICOS

ANEXOS: La Solicitud de Patente Europea arriba mencionada No. 99123803.1; Certificación del Presidente de la Oficina Europea de Patentes.

Texto en Inglés, Alemán y Francés

Oficina Europea de Patentes

Los documentos anexos son copias exactas de la solicitud Europea de Patentes descrita en la página siguiente, tal como fue originalmente presentada.

Solicitud de Patente No. 99123803.1

Por el Presidente de la Oficina Europea de Patentes

**(Firma Ilegible)
I.L.C.HATTEN-HECKMAN**

LA HAYA, el 26/10/00

SELLO ADHERIDO

Oficina Europea de Patentes

Hoja 2 del Certificado

Solicitud No. 99123803.1

Fecha de Presentación: 01/12/99

**Solicitante(s):
UCB, S.A.
1070 Bruselas
BÉLGICA**

**Título de la Invención:
Composición de levetiracetam y otro compuesto, y sus usos terapéuticos**

105
2
42104

Prioridad(es) reivindicada(s)

País:

Fecha:

Número de Presentación:

Clasificación Internacional de Patentes

AG1K31/55, AG1K31/51, AG1K31/56, AG1K31/40

Estados Contratantes designados a la fecha de presentación:

AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE

Notas:

Ver título original en la página 1 de la descripción

Composición de levetiracetam y usos terapéuticos

REIVINDICACIONES

1. Una composición farmacéutica que comprende levetiracetam y por lo menos, un compuesto que induce inhibición neural mediada por los receptores GABA_A.

2. La composición farmacéutica de la reivindicación 1, caracterizada porque el compuesto que induce inhibición neural mediada por los receptores GABA_A se escoge entre benzodiazepinas, barbituratos, esteroides y ácido valproico o sus sales farmacéuticamente aceptables.

3. La composición farmacéutica de la reivindicación 2 caracterizada por que el compuesto que induce inhibición neural mediada por los receptores GABA_A se selecciona entre benzodiazepinas, barbituratos, esteroides, y ácido valproico, y las 1,5 benzodiazepinas, tales como clobazam.

4. La composición farmacéutica de la reivindicación 2, caracterizada porque los barbituratos incluyen fenobarbital y pentobarbital.

5. La composición farmacéutica de la reivindicación 2, caracterizada porque el ácido valproico o sus sales terapéuticamente aceptables se escogen entre ácido valproico, valpromuro, pivoxil valproato, valproato de sodio y valproato semi sódico.

6. La composición farmacéutica de la reivindicación 5, caracterizada porque el compuesto que induce una inhibición neural mediada por los receptores GABA_A es valproato de sodio.

7. La composición farmacéutica de la reivindicación 1, caracterizada por que incluye una cantidad terapéuticamente efectiva del compuesto que induce inhibición neural mediada por los receptores GABA_A y una cantidad terapéuticamente efectiva de levetiracetam en la relación entre 2 y 15.

8. Un uso de la composición farmacéutica de la reivindicación 1, para el tratamiento de enfermedad seleccionada entre epilepsia, abstinencia de alcohol, temblor, trastorno bipolar, manía, trastorno compulsivo obsesivo, trastorno pánico, ansiedad y trastornos de ansiedad, depresión, migraña, cefalalgia, trastornos de dolor, isquemia y trauma de la cabeza.

9. Un uso de la composición farmacéutica de la reivindicación 1 para la fabricación de un medicamento para una aplicación terapéutica en una enfermedad seleccionada entre epilepsia, abstinencia de alcohol, temblor, trastorno bipolar, manía, trastorno compulsivo obsesivo, trastorno pánico, ansiedad y trastornos de ansiedad, depresión, migraña, cefalalgia, trastornos de dolor, isquemia y trauma de la cabeza.

Extracto

Composición de levetiracetam y usos terapéuticos

Esta invención se relaciona con nuevas composiciones farmacéuticas que comprenden levetiracetam y por lo menos un compuesto que induce una inhibición neural mediada por los receptores GABA_A.

ES TRADUCCIÓN FIEL Y COMPLETA DE LAS REIVINDICACIONES CONTENIDAS EN EL DOCUMENTO ANEXO TERMINADA ESTE 2 DE MARZO, 2001.

16 99. Colombia
400 83664
107

DOCUMENT OF ASSIGNMENT OF
PATENT

ASSIGNMENT

The undersigned

Yves LAMBERTY, a Belgian citizen.
Alain MATAGNE, a Belgian citizen.
Henrik KLITGAARD, a Danish citizen.
Tony WAEGEMANS, a Belgian citizen.

acting as inventors

of A pyrrolidinesacetamide derivative alone or in combination
for treatment of CNS disorders

with domicile in

Yves LAMBERTY, a Belgian citizen, residing at rue de la Vallée 10, B-1440 BRAINE-LE-CHATEAU, Belgium;
Alain MATAGNE, a Belgian citizen, residing at Allée des Sorbiers 3, B-6280 GERPINNES, Belgium; Henrik KLITGAARD, a
Danish citizen, residing at avenue Wolvendael 155, B-1180 BRUXELLES, Belgium;
Tony WAEGEMANS, a Belgian citizen, residing at Tienstevenweg 348, B-3000 LEUVEN, Belgium.

hereby declares that it assigns all rights of ownership as well as
all rights and privilege relating thereto without exception over
the following Patent in Colombia:

Title: "A pyrrolidinesacetamide derivative alone or in
combination for treatment of CNS disorders

to UCB, S.A.

domiciled in
Belgium

The assignor and the assignee sign this document as proof of
their acceptance of the assignment.

Given and signed on the day
of

DOCUMENTO DE TRASPASO DE
PATENTE

CESION

El suscrito

en calidad de

de

con domicilio en


declara por el presente documento que cede todos los derechos
de propiedad que le correspondan, así como las prerrogativas,
sin excepción alguna, sobre la siguiente Patente en Colombia:



a

domiciliada en

El cedente y el cesionario firman este documento como prueba
de su aceptación de la cesión.

Dado y firmado a los días del mes
de


Signature of Assignor
Yves LAMBERTY

Alain MATAGNE

Henrik KLITGAARD

Firma del cedente
Tony WAEGEMANS

UCB, S.A. of 80 Allée de la Recherche, B-1070
BRUXELLES, Belgium

Signature of Assignee

Firma del cesionario


Henriette VAN CAENEDEM, Proxy and Legal
Representative

I, Thierry VAN HALTEREN, Notary Public practising in Brussels, Belgium, do hereby certify and attest that the signature set on this document is/are stated to be the signature of M. Alain Delvenne, Mr. Vice President of the Board of Directors, Mr. Tom Dierckx and Mr. Wim Van Langem Brussels, November 23rd, 2000

[Handwritten signature]

T. VAN HALTEREN
NOTAIRE
18 de l'Association 38
1000 BRUXELLES

CONSULADO DE COLOMBIA
BRUSSELES, BELGICA 23 NOV. 2000
NC. 935

Previa la confrontación correspondiente DA FE que la firma que aparece en este documento es similar a la registrada aquí por M. Delvenne et al. Delegado del Ministerio de Relaciones Exteriores de Bélgica.

El Cónsul no asume responsabilidad por el contenido del documento.



Vu la légalisation de la signature de
M. Alain Delvenne, Mr. Vice President of the Board of Directors, Mr. Tom Dierckx and Mr. Wim Van Langem
apposée sur le présent document.
Bruxelles, le 23-11-2000

Par le Ministre des Affaires Étrangères
Le Fonctionnaire délégué,
N° DELVENNE (4)

PAGADO IMPUESTO DE TIMBRE

[Handwritten signature]
MAURICIO GONZALEZ LOPEZ
Cónsul General de Colombia

NO SE ASUME
RESPONSABILIDAD DEL TEXTO

2000 DEC -11-2

JEFE DE LEGALIZACIONES
SANTAFE DE BOGOTA

MINISTERIO DE RELACIONES
EXTERIORES

[Handwritten signature]

575569

CUYA FIRMA APARECE EN EL

DOCUMENTO RESEÑA

LAS FUNCIONES INDICADAS

TRADUCCIÓN DEL INGLÉS AL ESPAÑOL de las legalizaciones que se encuentran a continuación de un **DOCUMENTO DE TRASPASO DE PATENTE** otorgado por **Yves LAMBERTY, Alain MATAGNE, Henrik KLITGAARD y Tony WAEGEMANS** domiciliados en Bélgica, en su calidad de inventores de un derivado de pirrolidíneacetamina solo o en combinación, para trastornos del sistema nervioso central a **UCB, S.A.** sociedad domiciliada en **60 Allée de la Recherche, B-1070, BRUSELAS, Bélgica**, representada por **Henriette VAN CAENEGEM**, apoderada y Representante legal, y firmado el 22 de Noviembre, las cuales para su identificación se sellan con el Sello del Traductor al mismo tiempo que la presente. El texto del documento no se traduce ya que se encuentra en Español.

Al reverso **EN INGLÉS** Yo, **Thierry VAN HALTEREN**, Notario Público, en ejercicio en Bruselas, Bélgica, por medio de la presente certifico y atestigo que la(s) firma(s) colocada(s) en el presente documento se declaran como las firmas de **Alain MATAGNE, Yves LAMBERTY, Henrik KLITGAARD, Tony WAEGEMANS y Henriette VAN CAENEGEM**.

Bruselas 22 de Noviembre del 2000

FIRMA Y SELLO DEL NOTARIO

EN FRANCES : Visto para la legalización de la firma de **Thierry VAN HALTEREN**, Notario, colocada en el presente documento. Bruselas 23-11-2000-12-11.

Por el Ministerio de Asuntos Extranjeros. El Funcionario Encargado. **DELVENNE CH.**

EN ESPAÑOL: Sello del Consulado de Colombia en París, identificado con el No. 935 y fechado 23 de Noviembre de 2000, certificando la firma de **DELVENNE CH**, debidamente firmado por el Cónsul General Colombia en Bruselas **MAURICIO GONZALEZ LOPEZ**, que por estar en español no se traduce.

Sobre el margen izquierdo se aprecian dos sellos de caucho en tinta azul: Uno del Ministerio de Relaciones Exteriores con el número 575569 y el segundo del Jefe de Legalizaciones fechado: 2000 Dic. 1.

TRADUCTORA : MARIA EUGENIA MEDINA DE SANCHEZ

FECHA: martes 12 de diciembre de 2000

FIRMA Y SELLO DEL TRADUCTOR :


MARIA EUGENIA DE SANCHEZ
TRADUCTORA OFICIAL
RESOLUCION No. 1041 DEL
SECRETARIO DE FOMENTO

MINISTERIO DE RELACIONES
EXTERIORES

49161

CUYA FIRMA APARECE EN EL
DOCUMENTO DEFECHADO
LAS FUERZAS MILITARES

1.º SE AGUIRRE
F. SABIDO

709 DIC 13 A 2 11 5

JEFE DE LEGALIZACIONES
SANTAFE DE BOGOTA D.C.

43

2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 113

Radicación no 00-99771
Concepto Técnico no 1427

Clasificación Internacional de Patente: A61K 31/40

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

- SI ☒ NO ☐ Contiene un resumen de la invención (Art.26-e).
- SI ☒ NO ☐ Contiene el título o nombre de la invención (Art.27-d).
- SI ☒ NO ☐ Contiene la descripción de la invención (Art.26-b).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Contiene los dibujos necesarios para comprender la invención (Art.26-d).
- SI ☒ NO ☐ Contiene una o más reivindicaciones. (Art.26-c).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afroamericanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-i).
- SI ☐ NO ☐ NO ES APLICABLE ☒ La invención se refiere a un producto relativo a un material biológico. (Art.26-J).
- SI ☒ NO ☐ La prioridad coincide con la materia reivindicada.
- SI ☒ NO ☐ CUMPLE LOS REQUISITOS TÉCNICOS

OBSERVACIONES Y OTROS: SI ☒ NO ☐ ver hoja(s) anexa(s)

- Adjunta documento de cesión de derecho correspondientes a los folios 111, 112
- Adjunta la copia certificada de la patente, fuera del tiempo límite; correspondiente a los folios 76 - 91.

EXAMINADOR TÉCNICO
202048

Bogotá D. C octubre 01 de 2002

Carrera 13 No. 27-00 Piso 5 y 10
Conmutador: 334 12 21-2-3-4
Fax 281 31 25 e-mail: info@sic.gov.co
Santa Fe de Bogotá D.C. - Colombia



110

Industria y Comercio
SUPERINTENDENCIA

Folio: 114

2020
Bogotá DCDoctor
RAMIRO CASTRO DUQUE
Apoderado

REFERENCIA:	Radicación No.	00-01771
	Trámite	002
	Evento	001
	Actuación	416
	Oficio No.	1853
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía al extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

No obstante lo anterior, no se tendrá en cuenta la prioridad invocada, ya que no se presentó dentro de los dieciséis meses siguientes contados a partir de la fecha de presentación de la solicitud cuya prioridad se invoca.

Cúmplase

Dado en Bogotá DC, a los 26 DIC. 2002


ALIX CARMENZA CÉSPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones

202048

526

Carrera 13 No. 27-00 Fios 8 y 10
Conmutador: 334 12 21-2-3-4
Fax: 281 31 25 e-mail: info@aic.gov.co
Santa Fe de Bogotá D.C. - Colombia